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“An immune system of enormous complexity is present in all vertebrate 
animals. When we place a population of lymphocytes from such an 
animal in appropriate tissue culture fluid, and when we add an antigen, 
the lymphocytes will produce specific antibody molecules, in the absence 
of any nerve cells. I find it astonishing that the immune system embodies 
a degree of complexity which suggests some more or less superficial 
though striking analogies with human language and that this cognitive 
system has evolved and functions without assistance of the brain”. 
 
Niels K. Jerne 
'The Generative Grammar of the Immune System', Nobel Lecture, 8 Dec 1984. In Nobel Lectures: Physiology 
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Neonatal alloimmune thrombocytopenia (NAIT) is most commonly caused by destruction of 
foetal platelets by maternal antibodies reactive to human platelet antigen (HPA)-1a. The activation 
of antigen-primed B cells to differentiate to antibody-secreting plasma cells usually requires help 
from CD4 T cells. The strong association between anti-HPA-1a-production and the MHC allele 
HLA-DRB3*0101 supports that this notion is also valid in the context of NAIT, and suggests the 
activation of HPA-1a-specific T cells as the most critical event of immunization. 
 
In this study, an improved protocol for enrichment, identification and efficient isolation of HPA-
1a-specific CD4 T cells is presented. By replacing foetal bovine serum with human serum, 
enrichment of antigen-specific CD4 T cells improved dramatically. Identification and isolation of 
HPA-1a-specific CD4 T cells greatly improved when combining the CFSE proliferation assay 
with a second stimulation with antigen and subsequent assay for surface detection of TNF 
production. HPA-1a-specific CD4 T cells could also be identified in the CFSE proliferation assay 
as proliferating T cells with down-regulated expression of CD4. 
 
HPA-1a-specific T cells isolated from immunized women may serve as useful tools for 
investigating the cellular immune response to HPA-1a, and for developing strategies to prevent 
immunization in HPA-incompatible pregnancies, e.g. through TCR epitope mapping and 




Nearly all, living organisms possess some form of defence strategy to gain protection against 
potentially harmful pathogens. These mechanisms may range from the simple antibacterial 
peptides found in plants and insects to the highly sophisticated network of molecules, cells and 
tissues that make up the immune system of higher vertebrates. It is a well-known fact that a 
functional immune system is essential to human life, as common infections harmless to healthy 
individuals may be life threatening to people suffering from immune deficiencies. 
 
The human immune system is based on the recognition of non-self structures, enabling 
discrimination between structures of the individual’s own cells and tissues and foreign substances. 
When a pathogen enters the circulation by defeating the physical barriers made up by the skin and 
mucosal surfaces, proteins and cells of the innate immune system will target and seek to eradicate 
the invading pathogen. If necessary, cells of the innate immune system will also recruit cells of the 
adaptive immune system and activate these to provide specific targeting of the pathogen and 
induce immunological memory to provide lasting protection to subsequent infections by the same 
pathogen.  
 
Although essential for human life, the immune system may also cause disease. In some cases the 
immune system may be activated by self-structures, causing the immune system to target the 
individual’s own cells or tissues, as is the case with autoimmune diseases. In addition, our immune 
system will not only respond to foreign antigens from pathogens or toxins, but also to non-self 
structures from other individuals of the same species, in the settings of blood transfusions, organ 
transplants or pregnancy, resulting in alloimmune responses.  
 
1.1 Neonatal alloimmune thrombocytopenia is caused by foeto-maternal 
incompatibility in human platelet antigens (HPA) 
Neonatal alloimmune thrombocytopenia (NAIT) is a condition caused by destruction of foetal 
thrombocytes (platelets) by maternally produced platelet-reactive antibodies. In the Caucasian 
population, NAIT is most commonly caused by an incompatibility between maternal and foetal 
HPA-1 antigens, where an HPA-1a negative female may produce antibodies specific to HPA-1a 
when carrying an HPA-1a positive child. IgG anti-HPA-1a may cross the placenta by transcytosis 
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via the neonatal Fcγ-receptor (FcRγn) expressed on syncytiotrophoblasts in the foeto-maternal 
interface and enter the foetal circulation where they bind and opsonize foetal platelets (Figure 1.1). 
 
 
Figure 1.1 Schematic overview of the proposed pathogenesis of Neonatal alloimmune thrombocytopenia (1). 
 
 
1.1.1 Human platelets 
Blood platelets are the smallest blood components ranging from 2.0-5.0 μm in diameter. Platelets 
are non-nucleated structures produced by fragmentation of megakaryocyte cytoplasm in the bone 
marrow; where one megakaryocyte can give rise to about 4000 platelets.  
 
In the circulation, platelets are responsible for blood clotting and constriction of damaged blood 
vessels to prevent bleeding and to promote blood vessel repair. In addition, they are involved in 
regulating various processes including haemostasis, thrombosis and inflammation. In response to 
vascular injury, activated platelets will undergo adhesion to exposed subendothelial connective 
tissue through the glycoprotein (GP) IIb/GPIIIa receptor complex. Platelet adhesion promotes the 
release of granules containing various substances including ADP, serotonin, fibrinogen, lysosomal 
enzymes, β-thromboglobulin, heparin neutralizing factor and prostaglandins. In addition, 
arachidonate is released from the cell membrane and gives rise to thromboxane A2, which together 
with ADP promotes platelet aggregation at the site of vessel damage, leading to the formation of a 
haemostatic plug occluding the damaged vessel. 
 
The normal human platelet count is 150-450x109/L. Thrombocytopenia increases the risk of 
prolonged bleeding and is defined by a platelet count of <50x109 /L. NAIT usually presents as 
petechiae (small subcutaneous haematomas caused by capillary vessel lesions) and a platelet count 
below 50x109 /L in an otherwise healthy neonate. Severe thrombocytopenia (<20x109 /L) 
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dramatically increases the risk of intracranial haemorrhage (ICH). In severely affected neonates 
surviving intracranial haemorrhage, long term neurological complications including mental 
retardation, cerebral palsy and cortical blindness may arise (2-5).  
 
1.1.2 Human platelet antigens 
Human platelet antigens (HPA) are generated by single nucleotide polymorphisms (SNP) in 
platelet antigens, and are defined by immune responses between individuals that differ by 
allomorphisms at these sites. HPA-1 antigens are located on the β3-integrin (GPIIIa) of the 
GPIIb/GPIIIa complex, the major fibrinogen receptor on human platelets, and are generated by a 
Leu33/Pro33 amino acid difference (6). The GPIIb/GPIIIa integrins are expressed in normal 
amounts (50,000 – 80,000 copies) (7) on foetal platelets from approximately 16 weeks of gestation 
(8). The classification of HPAs is summarized in Table 1.1. 
 
The HPA alloantigens may cause production of HPA-reactive alloantibodies, which cause 
Neonatal Alloimmune Thrombocytopenia (NAIT) in incompatible pregnancies or post-transfusion 
purpura (PTP) in HPA-unmatched platelet transfusions. The SNPs that give rise to the different 
HPAs are listed in Table 1.2. 
 
Table 1.1 Nomenclature of Human Platelet Antigens (HPA). Modified from Metcalfe et al 2003 (9) 
System* Antigen* Glycoprotein CD System* Antigen* Glycoprotein CD 
HPA-1 HPA-1a GPIIIa CD61 HPA-5 HPA-5a GPIa CD49b 
 HPA-1b    HPA-5b   
HPA-2 HPA-2a GPIbα CD42b  HPA-6bw GPIIIa CD61 
 HPA-2b    HPA-7bw GPIIIa CD61 
HPA-3 HPA-3a GPIIb CD41  HPA-8bw GPIIIa CD61 
 HPA-3b    HPA-9bw GPIIb CD41 
HPA-4 HPA-4a GPIIIa CD61  HPA-10bw GPIIIa CD61 
 HPA-4b    HPA-11bw GPIIIa CD61 
     HPA-12bw GPIbβ CD42c 
     HPA-13bw GPIa DC49b 
     HPA-14bw GPIIIa CD61 
    HPA-15 HPA-15a CD109 CD109 
     HPA-15b   
      HPA-16bw GPIIIa CD61 
∗ HPA-systems are grouped based on the existence of alloantibodies defining a given alloantigen and its antithetical alloantigen. The HPA-systems 
are numbered chronologically according to their date of discovery. HPAs and their allotypes are designated alphabetically according to their 
frequency, with the more common variant designated ‘a’ and the less common variant designated ‘b’. A ‘w’ is added to the antigen name where an 




Table 1.2 Polymorphisms giving rise to human platelet antigens (HPA). Modified from Metcalfe et al 2003 (9) 
Antigen HGNC* Nucleotide change** Mature protein*** 
HPA-1 ITGB3 176T > C L33P 
HPA-2 GP1BA 482C > T T145M 
HPA-3 ITGA2B 2621T > G I843S 
HPA-4 ITGB3 506G > A R143Q 
HPA-5 ITGA2B 1600G > A E505K 
HPA-6w ITGB3 1544 G > A R489Q 
HPA-7w ITGB3 1297C > G P407A 
HPA-8w ITGB3 1984C > T R636C 
HPA-9w ITGA2B 2602G > A V837M 
HPA-10w ITGB3 263G > A R62Q 
HPA-11w ITGB3 1976G > A R633H 
HPA-12w GP1BB 119G > A G15E 
HPA-13w ITGA2B 2483C > T T799M 
HPA-14w ITGB3 1909_1911delAAG K611del 
HPA-15 CD109 2108C > A S682Y 
HPA-16w ITGB3 497C > T T140I 
* HGNC: Name of encoding gene (assigned by The Human Genome Organization (HUGO) Gene Nomenclature Committee; 
http://www.gene.ucl.ac.uk/nomenclature). 
** Nucleotide numbers are derived from the reference sequence in the NCBI database and may differ from numbers in the original publications 
describing the mutations. Nucleotide and amino acid substitution (mature protein column) is shown from the more common variant (a) to the less 
common variant (b). “Del” indicates a deletional mutation. 
*** Amino acid (single letter abbreviation) change corresponding to the nucleotide change. The number flanked by the amino acids give the 
positions in  the primary sequence of the protein. 
 
1.1.3 No effective treatment or prevention of NAIT is currently available 
To this day, no safe or effective treatment, or prevention of NAIT is available, and the detailed 
natural history of the immunization process is not completely understood. A large prospective 
screening and intervention study performed on 100 448 pregnant women in Norway revealed that 
almost 75 % of HPA-1a negative who produce anti-HPA-1a antibodies are immunized around 
delivery (10), suggesting that immunization in most cases is a consequence of foetomaternal 
haemorrhage. Another possible route of antigen exposure that needs to be considered is foeto-
maternal cell trafficking, which may cause foetal cells expressing HPA-1a (endothelial cells, 
invasive trophoblasts and thrombocytes) to enter the maternal circulation. In addition, invading 
foetal trophoblasts expressing the β3-integrin (αvβ3) replace endothelial cells of the spiral arteries 
in maternal placental endomethrium (11) and may also be a source of foetal HPA-1a exposed to 
maternal antigen presenting cells (APC). 
 
All factors that make a woman susceptible to immunization by HPA-1a are yet to be identified. So 
far it is known that females who produce anti-HPA-1a during pregnancy or after delivery are 
HPA-1a negative (HPA-1bb) and that the major histocompatibility complex (MHC) class II allele 
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HLA-DRB3*0101 is strongly associated with the development of NAIT (12;13). HLA-DRB3*0101 
is, in fact, present in over 90 % of women who produce anti-HPA-1a antibodies in connection 
with preganancy (14), compared to less than 30 % in the general population. The Norwegian 
screening and intervention study showed that anti-HPA-1a was detected in only 10,6 % of HPA-
1a negative pregnant women (14), suggesting a missing link in the prediction of antibody 
production in HPA-1 incompatible pregnancies that requires further investigation.  
 
The main focus of the management of NAIT is to prevent the consequences of ICH. NAIT occurs 
in approximately 1:1200 pregnancies, of which up to 30 % of the cases present with ICH 
(5;15;16). Two independent studies showed that 50-80 % of ICH cases due to NAIT occured in 
utero (5;17), meaning that in these cases, prophylactic strategies to prevent NAIT, rather that 
antenatal treatment is necessary. 
 
1.1.4 NAIT is the platelet counterpart of haemolytic disease of the newborn (HDN) 
The Rhesus (Rh) antigen system is the most important blood group system after the ABO system 
in terms of donor-recipient compatibility. The Rh antigens are located on transmembrane proteins 
on red blood cells (erythrocytes). The most important Rh antigens are D, C, c and e, where Rh-D 
is the most immunogenic antigen and the one that defines the Rh-factor of blood type designation. 
An individual positive for Rh-D will therefore be referred to as Rh positive (Rh+), while an 
individual negative for Rh-D will be referred to as Rh negative (Rh-) regardless of expression of 
any of the other Rh antigens. 
  
Immunization to the Rh-D antigen may occur in situations where an Rh-D negative woman is 
pregnant with an Rh-D positive child. Maternally produced antibodies targeting the Rh-D antigen 
may cross the placenta and cause destruction of the foetal/neonatal red blood cells, with 
haemolytic anaemia as the clinical consequence of Rh-D immunization, referred to as Haemolytic 
Disease of the Newborn (HDN). Anti-D transfer from mother to foetus occurs in multigravidae, 
and HDN rarely occurs in the clinic thanks to an effective anti-D prophylaxis administered to Rh-
D negative women after delivery of their first child. 
 
Previously the immunization to HPA-1a was assumed to occur in primigravidae (18), and for this 
reason, prophylactic strategies similar to that of preventing HDN was dismissed as a possibility to 
prevent NAIT. However, results from the Norwegian screening and intervention program revealed 
that in most cases, anti-HPA-1a was not detectable in the mother’s circulation until 6 weeks post 
 5
partum (10), suggesting that NAIT most likely occurs in the second incompatible pregnancy 
making it more similar to RhD-immunization than previously suggested. 
 
1.2 Antibody isotypes 
Each lymphocyte in the circulation will express identical lymphocyte receptors specific for the 
same epitope. The great diversity of epitope specificities displayed by the T cell receptor (TCR) 
and B cell receptor (BCR) repertoires is generated by randomized joining of gene segments 
encoding the variable regions of the lymphocyte receptors, a process referred to as recombinant 
gene rearrangement. 
 
The BCR is an immunoglobulin (Ig) transmembrane protein made up by four polypeptide chains; 
two heavy chains of approximately 50 kDa and two ~25 kDa light chains. The two heavy chains 
are joined together by two disulfide bonds, and one light chain is linked to each heavy chain via 
one disulfide bond. The heavy- and light chains each consist of a constant and a variable region, 
where the variable region of one heavy- and one light chain together make up the antigen-binding 
motif of the immunoglobulin molecule (Figure 1.2). The two heavy chains and the two light 
chains of each immunoglobulin molecule are identical, giving each immunoglobulin two identical 
antigen binding sites, and the ability to bind two identical structures simultaneously.   
 
 
        
Figure 1.2 An immunoglobulin molecule is a homodimer of two heavy- and two-light chains with constant (C) and 
variable (V) regions. The variable region of one heavy (VH) and one light (VL) forms the antigen-binding site of the 
immunoglobulin molecule, giving each molecule two identical antigen-binding sites. Modified from Janeway’s 
Immunobiology 7th edition (19) and Abbas’ Basic Immunology 3rd edition (20). 
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B lymphocytes are responsible for the production of antibodies targeting foreign structures 
recognized by the specific lymphocyte receptors of the adaptive immune system. If an antigen-
primed B cell is activated by a helper T cell specific to the same antigen, the activated B cell will 
differentiate to a plasma cell producing large amounts of secreted immunoglobulin, referred to as 
antibodies, of the same specificity as the membrane bound BCR. The three main effector functions 
of antibodies are neutralization, e.g. of viral antigens preventing virus entry to healthy cells, 
opsonization of bacteria and other foreign structures for uptake by phagocytes and activation of 
the complement system of the innate immune system.  
 
Several antibody isotypes may be produced by plasma cells (Figure 1.3), serving different effector 
functions, summarized in Table 1.3. The isotypes transferred from a mother to a foetus or neonate, 
are IgA and IgG. 
 
 
Figure 1.3 Schematic overview of the five different antibody isotypes produced by B cells, with their gene coding 
segments. The different isotypes are determined by the genes encoding the constant heavy chain region. Modified 
from Janeway’s Immunobiology 7th edition (19).  
 
Monomeric IgA will not be subject for transport across epithelial barriers, since transport of IgA is 
dependent on a specific joining segment containing a secretory signal that links IgA molecules to 
their dimeric form. Dimeric IgA is only released in bodily secretions such as tears, breast milk and 
mucus. However, IgA dimers with specificities for platelet antigens will not be of concern if 
transferred to the neonate via breast milk, as the only effector function of dimeric IgA is 
neutralization. In addition, IgA will remain in the gut mucosal layer and will not be transported 
over the gut epithelia of the neonate to enter the neonatal circulation. 
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Table 1.3 Specialized function and distribution of the different antibody isotypes. Modified from Janeway’s 
Immunobiology 7th edition (19) 
  IgM IgD IgG1 IgG2 IgG3 IgG4 IgA IgE 
Functional activity                
Neutralization + - ++ ++ ++ ++ ++ - 
Opsonization + - +++ * ++ + + - 
Sensitization for killing by NK cells - - ++ - ++ - - - 
Sensitization of mast cells - - + - + - - +++ 
Complement activation +++ - ++ + +++ - + - 
                 
Distribution                
+++ 
Transepithelial transport + - - - - - (dimer) - 
Transplacental transport - - +++ + ++ +/- - - 
*) IgG2 may excert opsonizing functional activity in the presence of an Fc receptor of a certain allotype found in approximately 50 % of the 
Caucasian population. 
 
As mentioned, most cases of NAIT are caused by an incompatibility in the expression of HPA-1 
antigens between an HPA-1a negative mother and an HPA-1a-positive child. During pregnancy, 
IgG antibodies are continuously transported across the placenta from the mother to the foetus via 
the FcRγn receptor. The trans-placental transport of IgG antibodies is meant to protect the foetus 
from infectious agents. If anti-HPA-1a IgG is present in the mother’s circulation during 
pregnancy, these will be transported along with these beneficial antibodies and enter the foetal 
circulation. Here, they may bind and opsonize foetal platelets expressing HPA-1a, rendering them 
for destruction. The destruction of antibody-coated platelets occurs mainly by Fcγ expressing 
phagocytes in the spleen, but may also be lysed by FcγRII (CD16)-expressing NK cells in 
antibody-dependent cell-mediated cytotoxicity (ADCC). 
 
1.3 T cells are involved in the generation of antibody-mediated immune 
responses 
NAIT is caused by destruction of foetal platelets coated with anti-HPA-1a produced by an HPA-
1a-negative female. The initiation of an antibody mediated immune response normally requires 
both helper T (TH) cells and B cells with specificity for epitopes on the same antigen.  
 
An immune response typically starts with activation of the innate immune system when a 
pathogen enters the body. When cells of the innate immune system encounter the pathogen they 
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will become activated and secrete chemoattractant molecules (chemokines) and cytokines to 
recruit and activate other cells of the immune system.  
 
Antigen presenting cells of the innate immune system are responsible for recruiting the highly 
specific adaptive immune system, through the activation of lymphocytes. These phagocytic cells 
are able to ingest pathogen, process antigenic protein to peptide fragments and present them on 
their cell surface bound to MHC molecules. Viral peptides and other intracellular antigens are 
usually presented on MHC class I molecules, expressed by most nucleated cells in the body, to 
CD8 T cells. Most bacterial and other extracellular antigens are usually presented on MHC class II 
molecules, expressed on professional antigen presenting cells (macrophages, dendritic cells and B 
cells), to CD4 T cells.  
 
After activation, CD8 T cells will proliferate, differentiate to cytotoxic T lymphocytes (CTL) and 
kill virus infected cells presenting viral peptide bound to MHC class I. Activated CD4 T cells will 
proliferate and differentiate into one of several different subtypes of T lymphocytes, determined 
by which cytokine stimuli they receive at the time of activation through the T cell receptor (TCR). 
Common to all subtypes is that they help orchestrate the adaptive immune response by activating 
and directing other effector functions of the immune system, and are therefore referred to as helper 
T (TH) cells. 
 
1.3.1 Activation of T cells 
In vivo, T cells are activated by antigenic peptide presented on MHC molecules on the surface of 
antigen presenting cells. The T cell receptor resembles one Fab-fragment of an antibody, and has 
one binding site for peptide:MHC. The T cell receptor is linked to several activation subunits 
designated CD3, that orchestrate the signalling events that lead to transcription of genes that 
promote T cell survival and proliferation upon TCR ligation. The most important genes that are 
transcribed are Interleukin (IL)-2 genes, that encode the T cell growth factor IL-2 and a high-
affinity IL-2 receptor. The transcription of these genes are activated by the transcription factors 
NFκB, NFAT and AP-1 that are activated and transported to the nucleus in response to activation 
signalling through the TCR. 
 
Naïve T cells require two signals for activation and proliferation. Signal one, which is an antigen-
specific activation through the TCR upon binding to peptide:MHC, and signal two which is given 
upon binding of CD28 on the T cell surface to the co-stimulatory molecule B7 expressed on APC. 
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Signal one activates intracellular signal pathways that induce transcription of IL-2 and the α-chain 
of the IL-2 receptor (IL-2Rα) that associates with the IL-2 receptor to make a high-affinity IL-2 
receptor. Signal two increase the initiation of IL-2 mRNA transcription and stabilisation of IL-2 
mRNA. 
 
Memory T cells are already differentiated to exert a specialized effector function after being 
activated through the TCR and CD28 in a previous immune response, and have undergone several 
phenotypic alterations that differ them from the naïve T cells. A memory T cell that already has 
overcome an activation barrier through antigen priming, selection and clonal expansion will only 
require ligation of the TCR and will not be dependent of a co-stimulatory signal through CD28 
when recruited to subsequent immune responses. For the same reason, stimulating peripheral 
blood mononuclear cells (PBMC) with antigen in vitro, should only lead to activation and specific 
proliferation of memory T cells with specificity to the given antigen.  
 
1.3.2 CD4 T cell lineages 
The two major subsets of CD4 T cells -TH1- and TH2 cells- have been well known since the early 
1990s. These subtypes are differentiated from naïve CD4 T cells in the periphery. In 2003 a third 
subtype of TH-cells differentiated from naïve peripheral CD4 T cells was described (21;22) and 
later designated TH17 cells  due to their interleukin(IL)-17 dominated cytokine profile (23-25). In 
addition, a fourth subtype differentiated from naïve CD4 T cells, induced regulatory T cells (iTreg), 
has been described (26-29). Natural killer (NK-) lymphocytes and natural regulatory T cells 
(nTreg) are also CD4 cells, but these do not differentiate from naïve peripheral CD4 T cells. 
Instead, they belong to distinct cell lineages differentiating in the thymus parallel to the cells that 
differentiate to become the naïve peripheral CD4 T cells that later give rise to the subtypes already 
described (30;31). More CD4 T cells subsets are likely to be discovered. In fact, an IL-22-
secreting subset has recently been suggested as a separate subset designated TH22-cells (32;33). 
 
The cytokine stimuli received by CD4 T cells at the time of activation, determines their 
differentiation and commitment to a given lineage. If the cell is stimulated by IL-4 and IL-2 at the 
time of activation, it will commit to the TH2 lineage (34-37), while differentiation to the TH1 
subtype occurs in response to IL-12 and Interferon(IFN)-γ (38;39). Differentiation to the TH17 
lineage is stimulated by transforming growth factor (TGF)-β and IL-6 (25;40;41).  
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TH1 and TH2 cells may be identified based on their pattern of cytokine production after activation, 
which is dominated by IFN-γ and IL-4, respectively. The cytokine profile of these two lineages is 
of importance to their effector functions. IFN-γ will stimulate macrophages to increase 
phagocytosis and antigen presentation, while IL-4 serves as a co-stimulatory factor during the 
activation of B cells.  
 
1.3.3 Evidence for involvement of T cells in immunization to HPA-1a 
The production of IgG antibodies directed towards HPA-1a in immunized females indicates that T 
cells are involved in the cellular immune response that may result in NAIT. This hypothesis is 
supported by several evidences obtained from prospective studies as well as investigations of cells 
derived from women who have given birth to affected children (42-44). 
T cells will only recognize antigen when presented by MHC molecules expressed on the surface of 
antigen presenting cells. The MHC variant HLA-DRB3*0101, which in association with the 
invariant HLA-DRA forms the MHC class II molecule HLA-DR52a, is present in over 90 % of 
women who produce anti-HPA-1a (14). By comparison, less than one third in the general 
population carry this allele, and the strong association between a specific MHC allele and IgG 
antibody production in response to HPA-1a, supports the notion that T cells with specificity to 
HPA-1a are involved in the immunization process (Figure 1.4). In addition, it has been shown that 
HLA-DRB3*0101 is able to bind and present HPA-1a-derived peptide (45).  
 
The SNP that defines the HPA-1a system is responsible for generating the immune response 
leading to the production of anti-HPA-1a. The immunogenicity of HPA-1a lies likely in the ability 
of the L33 residue to bind to a pocket in the peptide binding groove of HLA-DRB3*0101 (45), 
anchoring the antigen to the HLA-DR52a molecule. In 2007, the crystallographic structure of the 
HLA-DR52a molecule with HPA-1a L33 peptide in the groove, was published, predicting the 
binding (46). HPA-1b with a proline residue in position 33 fails to bind HLA-DR52a (45), 
suggesting that T cells reactive to HPA-1a are not eliminated from the T cell repertoire during 
thymic selection in HPA-1bb individuals. 
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β3-Integrin (HPA-1a) on fetal thrombocyte









Figure 1.4 T cells specific to HPA-1a are believed to activate HPA-1a antigen primed B cells. After activation by an 
HPA-1a-specific T cell, the B cell is believed to proliferate and differentiate to anti-HPA-1a secreting plasma cells.  
 
The involvement of T cells in the immune response leading to NAIT has previously been 
suggested by studies demonstrating HPA-1a specific proliferation of peripheral blood 
mononuclear cells (PBMC) from immunized mothers (42-44). In 2009 HPA-1a-specific T cell 
clones were isolated from women who had previously given birth to a child with NAIT (47;48), 
providing the first formal evidence that T cells with reactivity to HPA-1a are indeed present in the 
circulation of women who have produced HPA-1a-reactive antibodies in relation to a HPA-1-
incompatible pregnancy.   
 
1.4 Aim of study 
T cell clones isolated from HPA-1a-immunized women may serve as useful tools for investigating 
the cellular immune response to HPA-1a and as tools for developing potential strategies to prevent 
immunization in incompatible pregnancies i.e. through TCR epitope mapping and examinations of 
the immunogenicity of the HPA-1a antigen at the amino acid level.  
 
Cloning of antigen specific T cells is time consuming and with low cloning efficiency, larger 
patient samples (which may be difficult to obtain) are required in order to isolate specific clones. 
The main challenge in cloning HPA-1a specific T cell clones lays in the low frequency of T cells 
specific to a certain alloantigen in the circulation. In addition, spontaneous proliferating T cells of 
irrelevant specificities in in vitro proliferation assays makes the identification of antigen-specific T 
cells more challenging.  
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The aim of this study was to develop an improved protocol for enrichment, identification and 
isolation of HPA-1a specific T cells associated with NAIT. The main goal was to improve the 
cloning efficiency in order to isolate more clones from patient samples in a shorter period of time 
by seeking answers to the following questions: 
 
1. Can HPA-1a-specific T cells in PBMCs from alloimmunized women be enriched and 
isolated after a single stimuli and expansion in bulk culture? 
2. Can modifications in the culturing conditions help reduce the proliferation of T cells that 
proliferate without any obvious source of antigen-specific stimulation? 
3. Is the phenotype of HPA-1a-specific T cells distinguishable from the proliferating T cells 
with irrelevant specificities? 
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2. Materials and methods 
2.1 Materials 
 
Table 2.1 Cell lines used in the study 
              HLA Genotype       
Cell line Cell type Source A B C DRB1 DRB3 DQA1 DQB1 DPA1 DPB1 























Table 2.2 Peptides used in the study 
Antigen Peptide Amino acid sequence* Length of peptide 
HPA-1a L33 (integrin β3 19-38) VSPMCAWCSDEALPLGSPRC 20-mer 
HPA-1b P33 (integrin β3 19-38) VSPMCAWCSDEALPPGSPRC 20-mer 
Rye grass pollen Lol P1(191-210) ESWGAVWRIDTPDKLTGPFT 20-mer 
Cytomegalovirus (CMV) pp65 41-55 LLQTGIHVRVSQPSL 15-mer 
Cytomegalovirus (CMV) pp65 281-295 IIKPGKISHIMLDVA 15-mer 
Cytomegalovirus (CMV) pp65 485-499 PPWQAGILARNLVPM 15-mer 
*) Underlined amino acids serve as anchor residues for binding to HLA-DRB3*0101 (45). 
Peptides are synthesized by Eurogentec, Seraing, Belgium. 
 
Table 2.3 Cell culture medium and reagents used in the study 
Medium/reagent Distributor Usage 
Iscove's Modified Dulbecco Medium (IMDM) Lonza BioWhittaker (Verviers, Belgium) Cell culturing and handling 
Fetal Bovine Serum (FBS) Lonza BioWhittaker (Verviers, Belgium) Cell culturing and handling 
Human Serum (HS) from HPA-1bb donors 
Blood Bank and transfusion service, 
UNN Cell culturing and handling 
Penicillin-Streptomycin Lonza BioWhittaker (Verviers, Belgium) Cell culturing and handling 
Recombinant IL-2 (25 U/µl) PreproTech (London, UK) Cell culturing 
Recombinant IL-15 (500 ng/ml) PreproTech (London, UK) Cell culturing 
Carboxyfluorescein succinimidyl ester (CFSE) Invitrogen (Carlsbad, CA) Cell proliferation tracking assay 
Dimethyl sulfoxide (DMSO) 
WAK-chemie medical GMBH (Steinbach, 
Germany) Cell cryopreservation, reagent solute
Brefeldin A Fluka (Milwaukee, WI) Intracellular cytokine staining assay 
Adamantane-ethanol (AdEtOH)   MHC-peptide loading enhancer 
Lymphoprep density gradient medium Axis-Shield (Oslo, Norway) Isolation of PBMCs and platelets 
Optiprep density gradient medium Axis-Shield (Oslo, Norway) Isolation of monocytes and platelets 
Streptavidin-Alkaline Phosphatase conjugate Caltag Laboratories (Burlingame, CA) ELISPOT 







Table 2.4 Buffers used in the study 
Buffer Usage 
Phosphate buffered saline (PBS) General buffer and diluent 
PBS 0.2 % Bovine Serum Albumin (0.2 % PBSA) General buffer and diluent 
PBS 0.2 % Human Serum Albumin (0.2 % PHSA) General buffer and diluent 
PBS 0.5 % Fetal Bovine Serum Antibody diluent for ELISPOT 
PBS 0.01 % Tween20 Wash buffer for ELISPOT 
Saponin permeabilisation buffer Intracellular cytokine staining 
Fixation buffer (4 % paraformaldehyde) Intracellular cytokine staining 
 
Table 2.5 Monoclonal antibodies (mAbs) used in the study  
mAb Conjugate Distributor Usage 
Amount (μl) 
used in 100 μl 
staining volume 
anti-IFNγ purified BD Biosciences (San Jose, CA) ELISPOT -
anti-IFNγ biotin BD Biosciences (San Jose, CA) ELISPOT -
anti-IL-4 purified BD Biosciences (San Jose, CA) ELISPOT -
anti-IL-4 biotin BD Biosciences (San Jose, CA) ELISPOT -
anti-CD3 purified Caltag Laboratories (Carlsbad, CA) 
Expansion of T cell 
clones -
anti-CCR7 PE R&D Systems (Minneapolis, MN) Flow cytometry 5.0
anti-CD14 APC-Cy7 BD Biosciences (San Jose, CA) FACS/Flow cytometry  5.0
anti-CD25 PE BD Biosciences (San Jose, CA) Flow cytometry 4.0
anti-CD27 APC-Cy7 BioLegend (San Diego, CA) Flow cytometry 4.0
anti-CD29 APC-Cy7 BioLegend (San Diego, CA) Flow cytometry 4.0
anti-CD3 APC Invitrogen (Camarillo, CA) Flow cytometry/FACS 1.0
anti-CD3 Horizon-V450 BD Biosciences (San Jose, CA) Flow cytometry 1.0
anti-CD38 APC Invitrogen (Camarillo, CA) Flow cytometry 1.0
anti-CD4 PE-Alexa 610 Caltag Laboratories (Carlsbad, CA) Flow cytometry/FACS 1.0
anti-CD4 Horizon-V500 BD Biosciences (San Jose, CA) Flow cytometry 1.0
anti-CD45RA biotin BioLegend (San Diego, CA) Flow cytometry 0.2
anti-CD49d PE BioLegend (San Diego, CA) Flow cytometry 4.0
anti-CD56 biotin BioLegend (San Diego, CA) Flow cytometry/FACS 0.2
anti-CD62L PE-Cy7 BioLegend (San Diego, CA) Flow cytometry 4.0
anti-CD69 APC-Cy7 BioLegend (San Diego, CA) Flow cytometry/FACS 4.0
anti-CD8 PE Caltag Laboratories (Carlsbad, CA) Flow cytometry/FACS 0.5
anti-CLA biotin BioLegend (San Diego, CA) Flow cytometry 0.2
anti-HLA-DR PE-Cy7 BioLegend (San Diego, CA) Flow cytometry/FACS 2.0
anti-IFNγ APC Invitrogen (Camarillo, CA) 
Intracellular cytokine 
staining 0.5
anti-TNF PE BD Biosciences (San Jose, CA) Flow cytometry/FACS 0.75
anti-β7 integrin APC BioLegend (San Diego, CA) Flow cytometry 4.0
7- Amino-actinomycin D 








Table 2.6 Primers used in analysis of T cell receptor β-chain variable regions (TCRBV). Forward primers from two 
different publications were used. “MCOLA” primers published by Lee et al (49) and “Aka” primers published by 
Akatsuka et al (50). Common reverse primer BC63 and internal BC primers from Stuge et al (51) 
  Primer Sequence (5' - 3') 
PCR control UpActin CCGGGACCTGACTGACTA 
PCR control LoActin TACAGGTCTTTGCGGATGT 
Internal control  UpBC CGCTGTGTTTGAGCCATC 
Internal control  LoBC TGCTCAGGCAGTATCTGGA 
Reverse primer  BC63  GTGTGGCCTTTTGGGTGT 
Forward primers MCOLA BV1 CCTCCAGTTCCTCATTCAG 
  MCOLA BV2 ATGCTGATGGCAACTTCCA 
 MCOLA BV3 GGGCTACGGCTGATCTATTTC 
  MCOLA BV4 CACTGATCGCAACTGCAA 
 MCOLA BV5.1 GCCTTCAGTTCCTCTTTGA 
  MCOLA BV5.2 GGCCCCAGTTTATCTTTC 
 MCOLA BV5.4 TCCAGTTCCTCCTTTGGTATG 
  MCOLA BV 6.1 GAGTTTTTAATTTACTTCCAAGGCA 
 MCOLA BV 6.3 CCCAGAGTTTCTGACTTACTTC 
  MCOLABV 6.2 GGCCAGAGTTTCTGACTTATT 
 MCOLA BV7.1 GAAAGCTAAGAAGCCACCG 
  MCOLA BV7.2 TACAAGCAAAGTGCTAAGAAGC 
 MCOLA BV8.1 GGACTGGAGTTGCTCATTT 
  MCOLA BV8.3 CAGACAGACCATGATGCAA 
 MCOLA BV9 ATTTCTGAAGATAATGTTTAGC 
  MCOLA BV11 CTACACCTCATCCACTATTCCTA 
 MCOLA BV12.1 GGCTGAGGCTGATCCATTAC 
  MCOLA BV12.3 CATGGGCTGAGGCTGATCTA 
 MCOLA BV13.1 GGCTGAGGCTGATTCATTAC 
  MCOLA BV13.3 TGGGACTGAGGCTGATTT  
 MCOLA BV13.5 GGCTAAGGCTCATCCATTAT 
  MCOLA BV13.6 GGCTGAAGCTGATTTATTAT 
 MCOLA BV14 GGGCTTAAGGCAGATCTACT 
  MCOLA BV15 CCTACGGTTGATCTATTACTCCTT  
 MCOLA BV16 TCGACGTGTTATGGGAAA 
  MCOLA BV17 GACAGGACCCAGGGCAAG 
 MCOLA BV18  GGTCTGAAATTCATGGTTTATCT 
  MCOLA BV20 CCTCCAGCTGCTCTTCTA 
 MCOLA BV21.1 GAGCTTCTGGTTCAATTTCA 
  MCOLA BV21.2 GAGCTTCTGATTCGATATGAGA  
 MCOLA BV21.3 CCAAAGCTTCTGATTCAGTT  
  MCOLA BV22 CGAGTTTCTGGTTTCCTTTT 
 MCOLA BV23 CCCAGTTCCTCATTTCGTT 
  MCOLA BV24 CAAAGCTGCTGTTCCACTACTA 
  MCOLA BV25  GGTCCTGAAAAACGAGTTCAAG 
Reverse primer Aka TCRBC CTAAAACACAGCGACCTC 
Forward primers* Aka BV1 CTTGCACTCTGAACTAAACC 
  Aka BV2 TACCGTTCCCTGGACTTTC 
 Aka BV3 CAAAGTAACCCAGAGCTCG 
  Aka BV4 CCTGGACAGAGCCTGACA 
 Aka BV5 GAGWVRVARAGGAAACTTCCCT 
  Aka BV6 RMKCTCAGGTGTGATCCAA 
 Aka BV7a AACCTTCACCTACACGCCC 
  Aka BV7b TBCCTTCACCTACACACCC 
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Table 2.6 continued 
  Primer Sequence (5' - 3') 
 Aka BV8 ATGCRRGGACTGGAGTTG 
  Aka BV9 AATGAAACAGTTCCAAATCGC 
 Aka BV11 CGAGGAATGGAACTACACC 
  Aka BV12a TGAGATGTTCACCAGACTGA 
 Aka BV12b TGACGTGTCACCAGAACTTG 
  Aka BV13 ACTCAGACCCCAAAATTCC 
 Aka BV13.5 ATCACCCAGGCACCAACATCT 
  Aka BV14 ATAAGGGAGATGTTCCTGAA 
 Aka BV15 ATTCTCCCTGTCCCTAGAG 
  Aka BV16 TCAGTTCCCCAGCCACAG 
 Aka BV17 CAGAAAGGAGATATAGCTGAA 
  Aka BV18 GAGGAAGGTCTGAAATTCAT 
 Aka BV20 AGTTCATCCTGAGTTCTAAG 
  Aka BV21 CTCTCAAGATCCAGCCTG 
 Aka BV22 CCAGACTCCCAGCCATCA 
  Aka BV23 AAATGCTATCCTATCCCTAG 
 Aka BV24 CAATGAAGCAGACACCCCT 
  Aka BV25 ACAGGTCCTGAAAAACGAGT 
*)Nucleotide mismatches introduced to avoid primer-dimer formation are underlined.  K=G+T, M=A+C, R=A+G, W=A+T, B=C+G+T, 
D=A+G+T, V=A+C+G (50).  
 
Table 2.7 1x SuperScript III reverse transcriptase master mix 
Reagent Distributor Volume for 1x master mix (μl)
Random primers (500 μg/ml) Promega (Madison, WI) 2.0
dNTP 10 (10 mM)  QIAGEN (Hilden, Germany) 2.0
DTT (0.1 M) Invitrogen (Carlsbad, CA) 2.0
5x first strand buffer Invitrogen (Carlsbad, CA) 4.0
RNase inhibitor 40 u/μL) Promega (Madison, WI) 0.5
SuperScript III (200 u/μL) Invitrogen (Carlsbad, CA) 0.5
 
Table 2.8 1x master mix for PCR amplification of TCRBV cDNA 
Reagent Distributor Volume for 1x master mix (μL) 
10x PCR buffer mix QIAGEN 2.5
dNTP QIAGEN 0.5
H2O   9.5
BC63 (rev primer)  5.0
MCOLA BV (fwd primer)   5.0
HotStarTaq  QIAGEN 0.25
 
Table 2.9 1x Master mix for TCRBV sequencing using BigDye 3.1 
Reagent Distributor Volume for 1x master mix (μL) 
Sterile H2O   12.0 
BigDye 3.1 Applied Biosystems (Foster City, CA) 1.0 





2.2.1 Preparation of cells and platelets 
 
Isolation of PBMCs from blood buffy coats 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood buffy coats provided by 
the blood bank at the University hospital North Norway from donors giving written consent to the 
usage of their blood products for research purposes. The blood was diluted 1:1 in phosphate 
buffered saline (PBS) and layered on lymphoprep density gradient medium. After centrifugation at 
800g for 15 minutes without brakes, the leukocyte interface was collected and suspended in PBS 
with 0.2 % bovine serum albumin (0.2 % PBSA) or 0.2 % human serum albumin (0.2 % PHSA). 
The cells were pelleted at 400g for 6 minutes to remove platelets (platelet-rich supernatant were 
used for isolating platelets, see below), washed twice in 0.2 % PBSA or 0.2 % PHSA and 
resuspended in appropriate cell culture medium. 
 
Isolation of platelets 
When needed, platelets were isolated from the supernatant collected after isolation and washing of 
PBMC (above) by layering platelet rich 0.2 % PBSA on top of a 1.047 g/mL gradient made of 
Optiprep medium and PBS and centrifuging at 400g for 10 minutes. The platelet interface was 
collected and washed in 0.2 % PBSA by centrifugation at 950g for 10 minutes.  
 
Isolation of monocytes 
Monocytes were isolated from PBMCs using Optiprep medium. A working solution (WS) was 
prepared by mixing 4 mL Optiprep medium with 2 mL IMDM medium supplemented with 10 % 
FBS. A 1.070 g/L density gradient was prepared from the working solution by mixing 2.1 mL WS 
with 5.0 mL IMDM 10 % FBS. PBMCs were suspended in 2.5 mL IMDM 10% FBS + 2.5 mL 
WS and cooled on ice. 5.0 mL 1.070 g/mL density gradient was layered on top of the PBMC 
suspension, and 0.5 mL IMDM 10 % FBS was layered on top of the 1.070 g/L gradient. The 
preparation was centrifuged at 700g for 30 minutes without brakes, and the top interface (Figure 




Figure 2.1 A 1.070 g/L density gradient made from Optiprep medium was used to enrich for monocytes. 
 
Generation of B-lymphoblast cell line 
The B lymphoblast cell line D4BL4 was generated in our laboratory by Epstein-Barr virus (EBV) 
transformation of IgM- IgD- CD22+ (memory IgG+ B cells) cells from an HLA-DRB3*0101-
positive donor, as described by Ahlen et al (47). 
 
2.2.2 Peptide stimulation 
For studying the HPA-1a-specific T cell response, synthetic β3-integrin peptides spanning the 
L33/P33 polymorphism were used. 20-mer β3-integrin L33 peptide was used to resemble HPA-1a 
stimuli, while 20-mer β3-integrin P33 peptide was used to resemble the HPA-1b variant. As a 
negative control, 20-mer peptide derived from rye grass pollen protein, LolP1191-210, was used, as 
LolP1191-210 has been experimentally shown to bind the HLA-DR52a molecule (45). 
 
For control proliferation studies of T cells from cytomegalovirus (CMV)-positive donors, three 
different peptides derived from the CMV-associated protein pp65 were used. The selected 
peptides (Table 2.2) were chosen due to their ability to engage CD4 T cell responses (52). 
 
2.2.3 CFSE proliferation assay  
Carboxyfluorescein succinimidyl ester (CFSE) is an intracellular fluorescence dye used in cell 
proliferation assays to track cell divisions by flow cytometry (53). When incubated with cells, 
CFSE will penetrate the plasma membrane and bind cytosol components. When cell division takes 
place, CFSE bound components will be equally distributed to both daughter cells, leaving the 
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daughter cells with half the original amount of CFSE. Thus, when analyzing the cultured cells in 
flow cytometry, dividing cells will emit lower CFSE fluorescence than non-dividing cells, with a 
decrease CFSE amount proportional to the number of cell divisions. 
 
PBMCs were washed in 0.2 % PBSA or 0.2 % PHSA and stained with CFSE at 10 μg/mL in 1 mL 
0.1 % PBSA or 0.1 % PHSA at 37 °C for 10 minutes. 5 mL ice-cold culture medium was added, 
followed by 5 minutes incubation on wet ice to stop the staining process. Cells were pelleted at 
300 g for 4 minutes, washed three times in 0.2 % PBSA or 0.2 % PHSA and resuspended in 
culture medium. 
 
Cells were seeded out in 24 well plates at a density of 5 ⋅ 106 cells per well and stimulated with 1 
μM peptide or platelets (107 platelets per well) using HPA-1bb platelets as negative control. Cells 
were cultured for enrichment of antigen-specific cells at 37 °C in 7.5 % CO2 and atmospheric or 5 
% O2. Cells were cultured in IMDM medium supplemented with either 10 % FBS + 4 % human 
serum and Pen-Strep or 10 % human serum and Pen-Strep. The T cell growth factor interleukin 
(IL)-2 was added on days 5 and 10 (10 U/mL), and cells were analyzed by flow cytometry for 
proliferation and expression of selected surface markers by staining with fluorochrome-conjugated 
mAbs (Table 2.5). Single proliferating CD4 T cells were then sorted with the FACSAria (Becton 
Dickinson, NJ, USA) fluorescence activated cell sorter (FACS). 
 
2.2.4 Flow cytometry 
Flow cytometry is a fluidic- and laser-based method used for multiparameter analysis of single 
cells in suspension. Parameters measured can be cell size and complexity, as well as expression of 
various molecules – both extracellular and intracellular – with the use of fluorochrome-conjugated 
antibodies. In addition, cell function and responses can be measured by flow cytometry, using a 
number of different protocols and reagents (e.g. the CFSE proliferation assay described above). 
 
Data collected from each cell, which is up to ten different parameters in some of the experiments 
performed in this study, are analyzed consecutively in two-dimension plots where each cell is 
represented by a coordinate. Usually, 10,000 or more cells (events) are analyzed simultaneously in 




For flow cytometric analysis of cultured cells, cells were washed and resuspended in IMDM 10 % 
FBS in 4 mL Falcon tubes (Becton Dickinson, NJ, USA) and incubated with fluorochrome-
conjugated monoclonal antibodies (Table 2.5) in a final staining volume of 100 μl for 10 minutes 
in room temperature protected from light. When biotinylated mAbs were used, cells were stained 
with biotinylated mAbs for 10 minutes at room temperature in 100 μl IMDM 10 % FBS, washed 
and incubated with fluorochrome-conjugated streptavidin for 10 minutes at room temperature in 
100 μl IMDM 10 % FBS protected from light. Stained cells were finally washed in 4 mL PBS 0.2 
% BSA and resuspended in ∼300 μl 0.2 % PBSA for flow cytometric analysis. 
 
2.2.5 Fluorescent activated cell sorting  
In this study the FACSAria (Becton Dickinson) fluorescent activated cell sorter (FACS) was used 
to sort single proliferating T cells from peptide- or platelet-stimulated donor PBMCs. The FACS 
method is based on the principle of flow cytometry, with the option to isolate cells from chosen 
populations visualized by fluorochrome-conjugated monoclonal antibodies. When sorting cells, 
the cells are passing a laser, one by one, in a thin fluid stream. After passing the laser, a vibrating 
nozzle releases the fluid stream in open air and breaks up the fluid stream to droplets containing a 
single cell to be sorted. Each droplet receives an electric charge at the break-off-point from the 
fluid stream. The charged droplets pass through an electric field and are diverted into a designated 
container, e.g. a centrifuge tube or a 96-well plate. 
 
2.2.6 Expansion of T cell clones 
Single FACS-sorted CD4 T cell clones were expanded in round bottom 96 well plates (NUNC, 
Roskilde, Denmark) in IMDM 10 % FBS, 4 % HS (HPA-1bb) supplemented with Penicillin-
Streptomycin and purified monoclonal anti-CD3 (30 ng/mL). Irradiated D4BL4 B-lymphoblasts 
(2,500 cells/well) and irradiated PBMCs (20,000 cells/well) were used as feeder cells. 
Recombinant IL-2 (50 units/mL) was added at 4 day intervals, starting at day 1 of stimulation.  
 
Clonal HPA-1a specific T cells were expanded in flat bottom 24 well plates (NUNC) in IMDM 10 
% FBS, 4 % HS, PenStrep. T cells (5·105 cells/well) were expanded with purified monoclonal 
anti-CD3 (30 ng/mL), IL-15 (5 ng/mL) using irradiated B-lymphoblasts (106 cells/well) and 
irradiated PBMCs (4·106 cells/well) as feeder cells. IL-2 (50 U/mL) was added at 4 day intervals, 
starting at day 1 of stimulation. Cells were washed to remove anti-CD3 on day 7. Cells were 
expanded for 14 days before they were used in other assays. 
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2.2.7 ELISPOT assay 
The Enzyme-linked immunosorbent spot (ELISPOT) assay is a highly sensitive assay for 
detecting cytokine producing cells. In this study the ELISPOT assay was used to detect antigen-
specific T cell clones based on cytokine secretion after stimulation with HPA-1a antigen. 
 
MultiScreen HTS 96-well plates with nitrocellulose membrane (Millipore, Billerica, MA) were 
prepared with 30 μl 35 % Ethanol per well, washed three times in 200 μl PBS and coated with 
purified IFNγ or IL-4 monoclonal capture antibodies (10 μg/mL in 25 μl PBS per well). After 
incubation at 4 °C for 20 hours or longer, the mAb solution was decanted and the membranes were 
blocked with IMDM 10 % FBS 4 % Human HPA-1bb serum (HS), 200 μl per well at 37 °C for 2 
hours.  
 
Clonal T cells were added at a density of 1000-2000 cells/well in ~50 μl IMDM 10 % FBS 4 % 
HS with L33 peptide (5 μM) pulsed D4BL4 cells (50,000 cells per well) or autologous monocytes 
(50,000 cells per well) pulsed with HPA-1a+ platelets. D4BL4 lymphoblasts pulsed with LolP1 
peptide or non-pulsed autologous monocytes were used as controls. After incubation over night at 
37 °C, the cell suspensions were decanted and the wells were washed six times with 200 μl 0.01 % 
Tween20 in PBS and once in 200 μl PBS. Secondary biotinylated anti-IFNγ or anti-IL-4 
antibodies were added (1 μg/mL in 50 μl 0.5 % FBS in PBS) and the plates were incubated at 37 
°C for 2 hours. The wells were then washed 6 times in 0.01 % Tween20 in PBS and once in 200 μl 
PBS. Streptavidin-alkaline phosphatase conjugate was diluted 1:10,000 in PBS and 50 μl was 
added per well. After incubating in room temperature for 45 minutes, wells were washed 3 times 
with 200 μl 0.01 % Tween20 in PBS and 4 times in 200 μl PBS.  After washing, 50 μl of the 
colourless alkaline phosphatase substrate 5-bromo-4-chloro-3-indolyl phosphate-nitro blue 
tetrazolium (BCIP-NBT) was added to each well and incubated for 10 minutes protected from 
light. The substrate is cleaved by alkaline phosphatase to yield a coloured product that precipitates 
on the nitrocellulose membrane in concentric spots that correspond to cytokine secreting cells 





Figure 2.2 Steps of the Enzyme-Linked Immunosorbent SPOT (ELISPOT) assay. Figure from Hickling, J.K, 1998 
(54). 
 
2.2.8 Intracellular cytokine staining 
The intracellular cytokine staining-assay allows the detection of cytokine secreting cells with the 
use of flow cytometry. In this assay, cells are stimulated with antigen and reacted with Brefeldin-
A to block the secretory pathway of the cell, resulting in an intracellular accumulation of the 
cytokines produced in response to activation. Cells are then fixed in 4 % paraformaldehyde buffer 
and permeabilized with a saponin buffer to allow entry of cytokine-specific, fluorochrome-
conjugated monoclonal antibodies before flow cytrometic analysis.  
 
Intracellular cytokine staining of isolated T cell clones was performed to determine and confirm 
HPA-1a specificity: 
 
105 clonal T cells were labelled with CFSE to distinguish them from the peptide-pulsed B 
lymphoblasts used as antigen presenting cells. 105 HLA-DRB3*0101-positive B-lymphoblasts 
(D4BL4) were pulsed with L33 or LolP1 20-mer peptide for 3.5 hours at 37 °C in IMDM 
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(supplemented with 10 % FBS, 4 % HS and pen-strep) with 10 μM AdEtOH as a peptide loading 
enhancer. 
 
After pulsing, D4BL4 cells were irradiated for 800 s (receiving 12000 RAD) using a radioactive 
caesium source. Irradiated, peptide-pulsed D4BL4 cells were incubated with T cell clones in 100 
μL T cell medium with 10 μM Brefeldin-A over night at 37 °C, 7,5 % CO2 in 96-well round 
bottom cell culturing plates (NUNC). 
 
Cells were pelleted by centrifugation of the plates at 800g for 5 minutes and the supernatant was 
decanted. Cells were fixed in 100 μl fixation buffer (4 % paraformaldehyde) for 10 minutes at 
room temperature and washed once in PBS 0.2 % BSA before permeabilization with 100 μl 
saponin-buffer for 10 minutes at room temperature. Cells were pelleted by centrifugation and the 
supernatant was discarded. Cells were stained with 0,5 μl APC-conjugated anti-IFNγ in 20 μl 
permeabilisation buffer per well, and after 10 minutes incubation in room temperature protected 
from light, cells were washed in 200 μl permeabilisation buffer and resuspended in 50 μl 
permeabilisation buffer + 150 μl PBS 0.2 % BSA for flow cytometry. 
 
Lymphocytes were gated using side-scatter and forward-scatter parameters, and CFSEhi cells (T 
cell clones) were analysed for IFNγ expression (mean APC fluorescence intensity). 
 
2.2.9 TCRBV analysis  
Total RNA was isolated from T cell lysates using RNeasy Mini Kit (QIAGEN), and cDNA was 
synthesized from RNA by reverse transcription using SuperScript III Reverse Transcriptase. 
TCRBV family genes were determined by RQ-PCR and TCRBV genes were amplified by 
Polymerase Chain Reaction (PCR) (55) and sequenced as follows: 
 
RNA extraction from T cells 
Cells were washed twice in 1 ml PBS 0.3 % Ethylenediaminetetraacetic acid (EDTA) 0.1 % 
Diethylpyrocarbonate (DEPC) by sentrifugation at 6,000 g for 2 minutes. Cells were resuspended 
in 350 μl lysis buffer (buffer RLT, RN Easy MiniKit, Qiagen) with β-mercaptoethanol and lysed 
by vortexing for 30 seconds before addition of an equal volume of 70 % Ethanol.  
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The suspension was transferred to an RNeasy Spin Column (QIAGEN) placed in a collection tube. 
After centrifugation at 16,000 g for 30 seconds, flow through was discarded and 700 μl wash 
buffer RW1 (RNeasy Mini Kit) was added followed by centrifugation at 16,000 g, 30 seconds and 
flow through was discarded. 500 μl wash buffer RPE (RNeasy Mini Kit) was added. After 
centrifugation (16,000 g, 30 seconds), the RNeasy Spin Column was transferred to a new 
collection tube and 500 μl buffer RPE was added follwed by centrifugation (16,000 g, 30 seconds) 
and the spin column was placed into a RNAse free 1.5 mL eppendorf tube and centrifuged at 
16,000 g, 30 seconds. 50 μl RNAse free H2O was added to the membrane and after 3 minutes 
incubation, the tube was centrifuged at 16,000 g for 30 seconds, and the RNA was used further for 
cDNA synthesis by reverse transcription. 
 
cDNA synthesis from total RNA 
The RNA eluate was incubated at 70 °C for 10 minutes followed by 10 minute incubation on ice. 
11 μl SuperScript III master mix (Table 2.7) was added and cDNA synthesis was performed by the 
following program using a PCR thermal cycler: 22 °C 10 minutes, 42 °C 45 minutes, 99 °C 3 
minutes and 4 °C termination. Synthesized cDNA was eluted in sterile H2O to 300 μL for Real 
time PCR. 
 
Quantitative Real time PCR 
Quantitative Real time polymerase chain reaction (RQ-PCR) was performed using 5’ primers for 
all known functional genes encoding the variable region of the TCR β-chain (TCRBV) and a 
common 3’ primer (BC63 or Aka-TCRBC) for a specific sequence located in the β chain constant 
region (Table 2.6) using QuantiTect SYBR green PCR kit (QIAGEN) to detect the amplified PCR 
product. Primers amplifying a segment of the gene encoding the cytoskeleton molecule actin were 
used as PCR control, since actin is constitutively expressed by most cells. β-chain constant region 
primers were used as an internal control for amplification of TCR genes (Table 2.6). 
 
The following reactions were set up in 96 well MicroAmp plates (Applied Biosystems): 
 
Table 2.10 RT-PCR reactions for TCRBV analysis 
Reagent Volume (μL) Final  
Quantitect PCR SYBR mix (2x) 12.5 1x
Forward BV primer (1 μM) 5.0 200 nM
Common reverse primer BV63 (1 μM) 5.0 200 nM
cDNA 2.5
Total volume 25.0   
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The following cycles were run on ABIPrism 7900HT (Applied Biosystems) and data was 
analyzed using the SDS 2.2.2 software (Applied Biosystems): 
 
1 cycle 95 °C 
50 cycles 95 °C 
 58 °C 
 72 °C 
1 cycle 95 °C 
 60 °C 
 95 °C 
 
After determination of the TCRBV gene family used by the given T cell clone, TCRB PCR 
reactions were set up using the forward primer for the given TCRBV gene to amplify TCRBV 
cDNA for sequence analysis. PCR reaction was set up in two parallels in 0.2 mL PCR tubes with 
one non-template control (NTC) using water instead of cDNA. 
 
22.5 μL 1x master mix (table 2.8) and 2.5 μL cDNA were mixed and PCR was performed by the 
following cycles: 
 
1 cycle 95 °C 15 minutes
50 cycles 94 °C 30 seconds
 58 °C 30 seconds
 72 °C 15 seconds
1 cycle 72 °C 10 minutes
End 4 °C ∞
 
Sequencing reactions were set up by mixing 17 μl BigDye 3.1 master mix (Table 2.9), 1 μl primer 
(forward or reverse primer) and 2 μl PCR product. The reverse primer and forward primers were 
used in separate reactions. The gene products were amplified by PCR with the following cycles:  
 
1 cycle 95 °C 10 seconds 
1 cycle 58 °C 20 seconds 
 72 °C 30 seconds 
20 cycles 94 °C 15 seconds 
 55 °C 20 seconds 
 72 °C 30 seconds 
1 cycle 72 °C 10 minutes 
End 4 °C ∞ 
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Sequencing was performed by personnel at the sequencing facility at the University Hospital 
North Norway, by Sanger chain termination DNA sequencing (56) using BigDye 3.1 enzyme and 
nucleotide mix (Applied Biosystems). 
 
2.2.10 Phenotyping of HPA-1a specific T cells using monoclonal antibodies 
To determine if HPA-1a T cell clones display a phenotype distinguishable from other populations 
of proliferating cells, an extensive monoclonal antibody-panel to various activation-, subset-, and 
homing markers was designed and tested on clones and various control cell populations. Known 
surface markers for T cell activation, T cell subsets and tissue homing (Table 2.11) were chosen. 
Monoclonal anti-CD3 and anti-CD4 were included in all panels for gating purposes.  
 
Table 2.11 Surface markers included in phenotyping of HPA-1a specific T cell clones and controls 
Activation markers CD25 CD56 HLA-DR CD69   
Subset markers CCR7 CD45RA CD62L CD38 CD27 
Tissue homing markers CD49d CLA β7-integrin CD29   
 
To compare the phenotype of HPA-1a specific T cells to control populations of cells that may be 
present as background in CFSE proliferation assays, the following control populations were also 
phenotyped: CD3+CD4+ untreated PBMCs from a random blood donor, proliferating CD3+CD4+ 
cells from a random HLA-DRB3*0101-positive donor studied in a CFSE proliferation assay with 
HPA-1a antigen stimuli and proliferating CD3+CD4+ cells from two HPA-1a immunized donors 
studied with in a CFSE proliferation assay with HPA-1a antigen. 
 
2.2.11 Surface TNF assay 
In response to stimulation through the TCR, T cells secrete the cytokine TNF. TNF is synthesized 
as a 26-kDa protein first inserted to the plasma membrane immediately followed by an Ala76-Val77 
cleavage of the extracellular domain releasing the secreted 17 kDa TNF molecule, catalysed by the 
metalloprotease TNFα converting enzyme (TACE), also known as ADAM-17 (57).  
 
Inhibition of TACE using the TACE inhibitor TAPI-0, allows the detection of TNF on the surface 
of activated T cells by flow cytometry. This has already been done effective in studies of antigen-
specific CD8 T cells (unpublished data by Haney and Betts et al (58;59)), and here we tested if 
TACE inhibition to detect TNF producing cells is also applicable to CD4 T cells. Protocols for 
this assay were generously provided by (Danielle Haney at the University of Pennsylvania). 
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In order to test if TACE inhibition allowed the detection of TNF producing CD4 T cells, HPA-1a 
specific T cell clones were stimulated with L33 peptide and LolP1 control peptide in the presence 
of  TAPI-0 (10 μM) and 1.5 μl PE-conjugated anti-TNF in 200 μl culture medium in 15 mL 
conical polyethylene tubes. After 4.5 hours of incubation at 37 °C, cells were washed in 15 mL 
culture medium and once in 15 mL PBS 0.2 % BSA. Cells were resuspended in ∼300 μl PBS 0.2 
% BSA and transferred to 4 mL FACS tubes for flow cytometric analysis. 
 
For incorporation of the surface TNF assay in the sorting of single proliferating cells in the CFSE 
proliferation assay (section 2.2.3), cultured donor PBMCs were restimulated with peptide or 
platelets in the presence of TAPI-0 (10 μM) and anti-TNF for 4.5 hours before staining with 
fluorochrome-conjugated antibodies (anti-CD4, anti-CD8, anti-CD14) for FACS analysis and 












3.1 Stimulation with HPA-1a positive platelets resulted in down-regulation of 
CD4 co-receptor expression on proliferating T cells 
To determine if HPA-1a-specific CD4 T cells should be isolated from proliferating cells following 
a single stimulation with antigen, 5 ⋅ 106 peripheral blood mononuclear cells (PBMC) from a 
previously immunized donor (Donor 8) who gave birth to a child with NAIT were labelled with 
CFSE and cultured in two parallels with HPA-1aa platelets in 24-well culture plates for 14 days. 
HPA-1bb platelets were used as negative control: 
 
a) 








Figure 3.1 a) CFSE Proliferation assay of Donor 8 PBMCs performed on day 14 after a single stimulation with HPA-
1a+ platelets and HPA-1a- platelets. Proliferating cells with down-regulated surface CD4 expression are indicated 
(arrow). b) Single cells were sorted from gates P8 and P3 with FACSAria and expanded in culture. 
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A marked down-regulation of CD4 cell surface expression was observed in a subpopulation of 
cells proliferating in response to HPA-1a-positive platelets (Figure 3.1 a). Single cells were sorted 
using FACSAria from two populations of proliferating CD4 T cells (Figure 3.1 b); one population 
of high proliferation, and one population of slight lower proliferation, with marked CD4 down 
regulation.  
 
3.2 HPA-1a-specific T cell clones can be isolated from a population of CD4-
down-regulated T cells 
Single sorted CD4 T cells were expanded in culture and proliferating clones were tested for HPA-
1a-specificity by IFNγ and IL-4 ELISPOT. Clones secreting cytokines in response to HPA-1a 
antigen and not to control antigen were defined as specifically activated by HPA-1a.  
 
Regions P8 and P3 (Figure 3.1 b) gave rise to 50 and 30 proliferating clones, respectively. Of the 
50 clones from the region of higher proliferation (P8), no clones showed specificity to HPA-1a 
antigen. Of the 30 clones originating from the P3 region of proliferating cells with down regulated 












Control              L33                No trc.        HPA-1aa trc.
 
Figure 3.2 HPA-1a-specificity of proliferating T cell clones was determined by the ELISPOT assay detecting IFNγ 
(top) and IL-4 (bottom) secretion in response to HPA-1a antigen stimuli. Clone D7T4 used as positive control has 
previously been isolated in our laboratory and published (47). 
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The IFNγ- and IL-4-secretion in response to HPA-1a platelets and HPA-1a peptide only, confirms 
the specificity of these clones to the HPA-1a antigen. To determine the clonality of the isolated 
HPA-1a-specific T cell clones, sequencing of the variable region of the T cell receptor β-chain 
(TCRBV-sequencing) was performed. Sequences were analyzed using Sequence Scanner v1.0 
(Applied Biosystems) and the IMGT/V-quest software available at http://www.imgt.org (60). 
Analyzed sequences were aligned in BioEdit 7.0.3 (61). As shown in figures 3.3 and 3.4, the 
TCRBV region of clones D8T2 and D8T22 were identical, while the D8T48 clone was a unique 
clone. Figure 3.5 shows a schematic illustration of the predicted CDR regions of the T cell 
receptor, which are the domains making contact with MHC:peptide, with the CDR3 domain being 
the most variable motif. 
 
 
Figure 3.3 Sequence alignment of D8T48 TCR encoding genes. 
 
 
Figure 3.4 Sequence alignment of D8T2 and D8T22 TCR encoding genes. 
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Color menu for CDR-IMGT
[0, 122, 0]CDR3-IMGT (Light)[#46D500][70, 213, 0]
CDR2-IMGT 
(Light)[#0000E4][200, 0, 0]CDR1-IMGT (Light)






Figure 3.5 Schematic visualizations of the proposed amino acid sequences of the T cell receptor CDR regions reveal 
the CDR3 regions (purple domain) of the D8T2 / D8T22 and D8T48 T cell receptor. This analysis was performed 
using the IMGT/Collier-de-Perles tool available at http://www.imgt.org.  IMGT unique numbering for V-domains 
determines the lengths of CDR-IMGT (62). 
 
Table 3.1 Summary of TRBV rearrangements for T cell receptors of clonal cell lines, using IMGT nomenclature (63) 
 
    TCRB rearrangements            CDR3 
HPA-1a-specific clone TRBV TRBD TRBJ TRBC   Length Amino acid sequence 
D8T2 12-3*01 2*01 or 2*02 2-6*01 2   13 ASRTSGREANVLT 
D8T22 12-3*01 2*01 or 2*02 2-6*01 2  13 ASRTSGREANVLT 
D8T48 7-2*01 or 7-2*04 1*01 1-2*01 1   11 ASSSDILRGYT 
 
The specificity of the T cell clones to HPA-1a was also confirmed by intracellular cytokine 
staining measuring the production of IFNγ (as APC fluorescence intensity) in response to HPA-1a 
antigen stimuli (Figure 3.6). These findings demonstrate that HPA-1a-specific T cells can be 
isolated following a single stimulation of PBMCs from immunized donors, and CD4 down-















   
   
   
   
   
   
   
   
   
   








Figure 3.6 Intracellular cytokine staining measuring IFNγ production (as APC fluorescence intensity) in response to 




Table 3.2 Summary of HPA-1a-specific CD4 T cell clones isolated from immunized donor # 8 
Stimuli Population Proliferating clones HPA-1a specific clones 
HPA-1a trc CFSE low, CD4 high 50 0 
HPA-1a trc CFSE low, CD4 low 30 3 (10 %) 
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3.3 Modifications of the composition of cell culture medium resulted in a 
higher proportion of proliferating T cells in cultures stimulated with specific 
antigen compared to control cultures 
Since many of the proliferating T cells were not HPA-1a-specific (only 3 clones out of 30 from 
the CFSElow, CD4low population), various culture conditions were tested to determine if 
background proliferation of T cells with irrelevant specificities could be reduced.  
 
In order to optimize conditions for enrichment of antigen-specific CD4 T cells in vitro, and 
considering the relatively small number of valuable patient samples, a larger source of PBMCs 
with specific T cell responses against a known antigen was needed. Since many people (around 40 
%) are infected with cytomegalovirus (CMV) and commonly targeted T cell epitopes in the CMV 
protein pp65 are known, PBMCs from random blood donors were screened using pp65 peptide 
epitopes to identify donors who had such responses. CMV-positive donors were identified by 
assaying donor PBMCs by IFNγ ELISPOT (Figure 3.7). Donors with cells secreting IFNγ in 
response to CMV derived peptides only were defined as CMV-positive. CFSE proliferation assays 
were performed on PBMCs from these donors. 
 
6235 62416238 6250
pp65        LolP1      nostim pp65       LolP1      nostim pp65       LolP1      nostim pp65        LolP1      nostim
 
Figure 3.7 IFNγ ELISPOTS of PBMCs (3⋅105 cells/well) from random blood donors stimulated with pp65 derived 
peptides at 3 μM for 3 days. Donors 6235 and 6241 were defined as CMV-positive based on their release of IFNγ in 
response to pp65 peptide only. Each column represents eight replicates of the given stimuli. 
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PBMCs from CMV-positive donors 6235 and 6241 were labelled with CFSE and stimulated with 
a peptide pool of the CMV pp65-derived peptides pp6541-55, pp65281-295 and pp65485-499 at a final 
peptide concentration of 3 μM. Cells were grown for 14 days in culture under different culturing 
conditions (Table 3.3). Recombinant IL-2 (10 U/mL) was added to the cultures on days 5, 8 and 
11 and analyzed for proliferation by flow cytometry on days 3, 6 and 14 (Table 3.4, Figure 3.8). 
The difference in size between CMV peptide-stimulated and control stimulated proliferating 
populations was interpreted as antigen-specific responses.  
 
Table 3.3 Variations in serum- and oxygen content were compared to test determine optimal conditions for 
enrichment of antigen-specific T cells 
Conditions Medium Serum O2 level CO2 level 
1 IMDM 10 % FBS Atmospheric 7.5 % 
      4 % Human serum   
2 IMDM 10 % Human serum Atmospheric 7.5 % 
     
3 IMDM 10 % FBS 5 % 7.5 % 
      4 % Human serum   
     
4 IMDM 10 % Human serum 5 % 7.5 % 
 
Table 3.4 Proportion of proliferating CD4 T cells in response to CMV antigen (pp65 peptide pool) compared to non-
stimulated controls (no peptide). Data are collected from CFSE proliferation assay performed on days 3, 6 and 14  
      
 
Proliferating CD4 T cells (%)  
Day Serum Oxygen Donor no peptide* pp65 peptide pool* Fold increase** 
3 10 % FBS, 4 % HS Atmospheric 6235 1,03 1,04 1.0 
      6241 0,68 0,72 1.1 
   5 % 6235 1,16 1,06 0.9 
   6241 1,16 1,10 0.9 
  10 % HS Atmospheric 6235 1,28 1,02 0.8 
      6241 0,68 0,58 0.9 
  5 % 6235 1,02 1,15 1.1 
      6241 0,62 0,98 1.6 
6 10 % FBS, 4 % HS Atmospheric 6235 2,37 5,89 2.5 
      6241 1,31 1,83 1.4 
  5 % 6235 2,96 3,69 1.2 
   6241 1,26 2,66 2.1 
  10 % HS Atmospheric 6235 1,27 2,78 2.2 
      6241 0,99 2,13 2.2 
  5 % 6235 1,47 1,45 1.0 
      6241 1,03 1,55 1.5 
14 10 % FBS, 4 % HS Atmospheric 6235 95,88 91,94 1.0 
      6241 89,94 93,50 1.0 
  5 % 6235 86,69 85,19 1.0 
   6241 82,05 84,06 1.0 
  10 % HS Atmospheric 6235 30,01 76,28 2.5 
      6241 50,35 93,57 1.9 
  5 % 6235 29,10 25,51 0.9 
      6241 55,82 88,46 1.6 
* Numbers indicate percent proliferating CD4 T cells of the total population of CD3 positive cells assayed. 







Figure 3.8 Fold increase of proliferating CD4 T cells (% of total CD3 cells) in response to pp65 peptide stimuli 
relative to negative control (no stimuli) for different enrichment conditions at day 3, 6 and 14 in CMV positive blood 
donors. A fold increase of 1.0 (indicated by a horizontal line) refers to no increased proliferation in pp65-stimulated 
cultures relative to the control. 
 
The findings from these experiments show that replacing FBS with human serum reduced 
proliferation of T cells with irrelevant specificities (an increased difference between “no peptide” 
and pp65 peptide was observed) and this difference was most prominent on day 6 after 
stimulation. No effect was observed by reducing O2 levels. 
 
3.4 No obvious phenotypic differences were detected when comparing non 
specific/spontaneous proliferating T cells with antigen-specific T cell clones 
 
Since CD4 down-regulation was found to be a potentially useful marker for identification of cells 
responding to specific antigen, a panel of monoclonal antibodies was used to determine if there 
were other phenotypic changes that could be helpful in distinguishing antigen-specific T cells 
from the proliferating T cells with irrelevant specificities. 
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Table 3.5* HPA-1a specific T cell (D8T2 and D8T48) phenotype compared to phenotype of CD3+CD4+ cells from 
random PBMCs and proliferating CD3+CD4+ cells from random donor (T42) PBMCs after stimulation with HPA-1a 
L33 peptide and LolP1 control peptide. Random donor T42 expresses the MHC class II molecule HLA-DRB3*0101, 
which is able to bind and present HPA-1a L33 peptide. Values represent median fluorescence intensity measured by 
Flow Cytometry 
  D8T2 D8T48 PBMCs T42 nostim T42 LolP1 T42 L33
CD25 1077.61 346.52 180.58 6005.00 8370.00 9977.29
CD56 1297.26 1293.18 227.07 298.79 335.67 364.25
HLA-DR 17060.98 23075.62 153.26 2856.54 4541.25 3881.19
CD69 3595.29 1961.88 45.88 1136.38 1193.51 965.95
CCR7 67.42 75.93 37.57 49.45 50.46 48.07
CD45RA 184.92 170.42 417.96 205.59 175.38 213.65
CD62L 53.71 43.51 10869.68 405.86 385.61 325.57
CD38 656.77 772.88 182.27 9515.62 7408.27 3703.52
CD27 3.01 3.01 1328.69 587.93 349.46 321.10
CD49d 2127.50 6525.67 676.40 7067.21 8139.81 5891.55
CLA 636.48 948.35 272.41 7068.85 8137.58 5890.29
β7-integrin 31515.50 43161.62 686.95 19849.95 18645.69 18311.55





Table 3.6* HPA-1a specific T cell (D8T2 and D8T48) phenotype compared to phenotype of proliferating CD3+CD4+ 
PBMCs from HPA-1a immunized donor 18 after stimulation with HPA-1a platelets or L33 peptide and HPA-1b / 
LolP1 controls. Values represent median fluorescence intensity measured by Flow Cytometry 
  D8T2 D8T48 D18 HPA-1bb D18 HPA-1aa D18 LolP1 D18 L33
CD25 1077.61 346.52 54.05 53.80 12930.41 12825.25
CD56 1297.26 1293.18 631.57 616.43 620.94 555.64
HLA-DR 17060.98 23075.62 1299.04 1446.80 1277.44 1734.54
CD69 3595.29 1961.88 126.68 140.86 129.79 116.23
CCR7 67.42 75.93 45.29 49.06 52.47 51.23
CD45RA 184.92 170.42 347.38 351.51 368.53 349.14
CD62L 53.71 43.51 2120.23 1707.06 1682.05 2366.39
CD38 656.77 772.88 7010.90 6490.56 8973.65 8796.80
CD27 3.01 3.01 431.31 537.70 300.78 394.97
CD49d 2127.50 6525.67 4104.34 5993.64 5935.54 5918.98
CLA 636.48 948.35 878.32 1070.06 1040.80 1124.31
β7-integrin 31515.50 43161.62 12380.35 13724.48 14364.02 11907.35








Table 3.7* HPA-1a specific T cell (D8T2 and D8T48) phenotype compared to phenotype of proliferating CD3+CD4+ 
PBMCs from HPA-1a immunized donor 19 after stimulation with HPA-1a platelets or L33 peptide and HPA-1b / 
LolP1 controls. Values represent median fluorescence intensity measured by Flow Cytometry 
  D8T2 D8T48 D19 HPA-1bb D19 HPA-1aa D19 LolP1 D19 L33
CD25 1077.61 346.52 13181.55 11842.93 13120.15 11447.17
CD56 1297.26 1293.18 665.13 633.07 614.77 608.16
HLA-DR 17060.98 23075.62 9021.33 10214.70 6833.04 5901.81
CD69 3595.29 1961.88 124.19 126.24 113.03 108.25
CCR7 67.42 75.93 56.31 51.48 53.10 57.43
CD45RA 184.92 170.42 4905.24 4026.20 3842.95 3890.33
CD62L 53.71 43.51 6715.27 7176.95 5312.02 5990.55
CD38 656.77 772.88 5941.62 5169.87 6400.89 6249.81
CD27 3.01 3.01 270.41 180.98 179.09 199.61
CD49d 2127.50 6525.67 5669.49 6202.52 5366.96 6247.47
CLA 636.48 948.35 1081.75 1023.56 928.13 535.06
β7-integrin 31515.50 43161.62 12799.80 13286.56 13325.79 16595.89
CD29 14338.79 11740.90 2121.67 2353.33 2028.68 2441.08




> 10 000 
 
No obvious differences were found between the HPA-1a-specific T cell clones and spontaneous 
proliferating T cells from PBMCs from either random donors or HPA-1a-immunized donors. 
 
3.5 The TACE inhibitor TAPI-0 can be used to allow detection of TNF-
production in activated HPA-1a-specific T cells as surface pro-TNF 
expression 
A feature that can be used to identify antigen-activated T cells is secretion of cytokines. While 
IFNγ measurement by flow cytometry requires fixation of the cells, a new method for surface 
staining for TNF could be performed on live cells (58;59). This method was tested on HPA-1a-
specific T cell clones in order to examinate the feasibility of this method in a strategy to increase 
the efficiency of identification and isolation of HPA-1a-specific T cells. 
 
T cell clones were labelled with CFSE (to distinguish them from B-lymphoblast cells in flow 
cytometry) and incubated with peptide-pulsed D4BL4 B-lymphoblasts or peptide only for 4.5 
hours in the presence of the TACE inhibitor TAPI-0 and monoclonal PE-conjugated anti-TNF and 










   
   
   
   
   




BL only BL+LolP1           BL+L33         No peptide LolP1                 L33
 
   b)                                                                                        c) 
              
Figure 3.9 TNF-production, measured as PE fluorescence intensity by flow cytometry in HPA-1a-specific T cell 
clones after stimulation with HPA-1a peptide-pulsed HLA-DRB3*0101-positive B lymphoblasts (D4BL4) (a, b) and 
in HPA-1a-specific T cell clones after stimulation with HPA-1a peptide only (a, c). 
 
As seen in Figure 3.9 a) and c), T cell clone D8T48 produce TNF in response to HPA-1a L33 
peptide stimuli in absence of antigen presenting cells, suggesting that the peptide can bind HLA-
DR molecules expressed on the T cell surface directly, and that the T cells can stimulate each 
other in culture. Three parallels of this experiment revealed that the extent of TNF-production in 
response to activation is different for these two clones. Still, this method was found to be suitable 
for viable identification of T cells responding to specific antigen-stimulation, and could likely be 
combined with the CFSE proliferation assay for enhanced efficiency in identification of HPA-1a-
specific T cells in donor PBMCs, as shown later. 
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3.6 Enhanced culture conditions resulted in a higher proportion of potential 
antigen-specific cells 
Following optimalization of culture conditions using PBMC from CMV-positive donors, these 
conditions were tested in donor PBMCs to see if the detection of HPA-1a-specific T cell 
proliferative responses would improve. 
 
Donor 8 PBMCs were stained with CFSE and stimulated with HPA-1aa platelets or L33 20-mer 
peptide using HPA-1bb platelets or LolP1 20-mer peptide as controls, respectively. The cells were 
cultured for 11 days at the optimal culturing conditions defined by the CMV-study (section 3.3) 
using IMDM cell culture medium supplemented with 10 % Human (HPA-1bb) serum and Pen-
Strep. Cells were incubated at 37 °C using atmospheric O2 content and 7.5 % CO2. Recombinant 
IL-2 (10 U/mL) was added to all wells on day 5. 
 
On days 3, 6 and 10 donor 8 PBMCs were collected and stained with anti-CD8 (PE), anti-CD3 
(APC), anti-CD14 (APC-Cy7) and anti-CD4 (PE-Alexa610) and analyzed for proliferation by 
flow cytometry. Flow data was analyzed using the FlowJo software (Treestar, Ashland. OR). A 
large lymphocyte gate was drawn using forward- and side-scatter parameters since stimulated T 
cells tend to increase in size. To avoid CD8 T cells and monocytes, CD8 and CD14 was used as 
“dump” markers. The CFSE proliferation assay was studied for CD3+CD8-CD14- lymphocytes*: 
 
Table 3.8 CFSE proliferation assay performed on stimulated Donor 8 PBMCs on days 3, 6 and 10 of stimulation 
  Proliferating CD4 T cells (%)  Proliferating CD4 T cells (%)   
Day LolP1** L33** Fold increase*** HPA-1bb trc.** HPA-1aa trc.** Fold increase***
3 0,16 0,58 3.6 1,07 2,23 2.1 
6 0,17 0,59 3.5 1,08 2,21 2.0 
10 15,39 24,48 1.6 3,69 67,93 18.4 
* On day 10, cells were not stained with anti-CD3 to avoid background secretion of TNF by cells that may be 
activated by the anti-CD3 antibody. 
** Numbers indicate percent proliferating CD4 T cells of the total population of CD3 positive cells assayed. 
** *Fold increase of CD4 T cells proliferating at various days after stimulation with HPA-1a antigen relative to 
negative control (LolP1 or HPA-1bb trc.). 
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Figure 3.10 Fold increase of proliferating CD4 T cells (% of total) from an HPA-1a-immunized donor in response to 
HPA-1a antigen stimuli relative to negative control at days 3, 6 and 10. A fold increase of 1.0 (indicated by a 
horizontal line) refers to no increased proliferation in HPA-1a antigen-stimulated cultures relative to the controls. 
 
 
CFSE proliferation assay performed on Donor 8 T cells on days 6 and 10 (Table 3.8, Appendix II 
and Figure 3.11) of stimulation revealed that the proportion of proliferating CD4 cells was 
markedly higher in response to stimuli with HPA-1a antigen compared to the controls. When 
performing flow cytometric analysis, lymphocytes were gated using forward- and side scatter 
parameters. On day 6 CD3+CD8-CD14- cells were analysed for expression of CFSE in 
combination with CD4. On day 10, cells the surface TNF assay was tested in addition to 
performing the CFSE vs CD4 proliferation analysis. To avoid background TNF secretion from 
TCR-mediated stimulation, cells were not stained with anti-CD3. CD8-CD14- lymphocytes were 
analyzed, and proliferating CD4 T cells were analyzed for TNF secretion as shown in Figure 3.11. 
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Figure 3.11 CFSE proliferation assay and surface TNF assay on Donor 8 PBMCs. On day 10 of proliferation after 
initial stimulation with antigen, the cells were stimulated again and assayed for TNF surface expression as detailed in 
the methods chapter. TNF expression is displayed for events in the upper left quadrant in the CFSE vs CD4 plots, as 
indicated (arrows). 
 
These findings demonstrate that the enhanced culture conditions indeed resulted in more specific 
proliferation to stimulation with HPA-1a antigen, and that a small portion of the proliferating cells 
react with anti-TNF mAb following restimulation with specific antigen. 
 
3.7 HPA-1a-specific T cells can be identified by a combination of the CFSE 
proliferation assay and surface TNF-expression 
On day 11 of stimulation, PBMCs were stimulated with L33 peptide or HPA-1a platelets in the 
presence of TAPI-0 and PE-conjugated anti-TNF for 4.5 hours. Cells were washed in IMDM 
medium and labelled with 7-AAD (to gate and eliminate dead cells) and fluorescence-labelled 
mAbs. CD8- CD14- 7-AAD- lymphocytes were analyzed (Figure 3.12) and single, proliferating 
CD4 T cells were sorted using FACSAria, and expanded with anti-CD3 (30 ng/mL) in round 
bottom 96 well plates using irradiated feeder cells (PBMCs and D4BL4 B-lymphoblasts). 
Recombinant IL-2 (50 U/mL) was added every four days, starting on day 1 of expansion. 
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Single cells were sorted from three different populations (Figure 3.12): one population of 
proliferating CD4 T cells (gate P6), one population of proliferating CD4 T cells with 
downregulated CD4 expression (gate P5) and one population of proliferating CD4 T cells 






















Figure 3.12 Single proliferating CD4 T cells were sorted from gates P4, P5 and P6 (60 cells from each region). The 
figure shows the sorting gates for peptide stimulated PBMCs. The same sorting gates were made for Donor 8 PBMCs 
stimulated with platelets. Cells were sorted from the P4 gates in L33 peptide-stimulated cultures and from gates P4, 
P5 and P6 in cultures stimulated with whole HPA-1a+ platelets. A compensation error is seen for CD4 due to missing 
settings for Horizon-V500 (conjugate on the used anti-CD4) on the FACSAria used for sorting. Settings for AmCyan 
were used. 
 
After expansion of single sorted cells in culture with anti-CD3, proliferating clones were analyzed 
by IFNγ and IL-4 ELISPOT assay (Figure 3.13). 9 out of 28 proliferating clones from different 
populations (summarized in Table 3.9) were specific to HPA-1a antigen. TCRB gene analysis and 
sequencing was performed for five of these clones (summarized in Table 3.10). The remaining 
four HPA-1a-specific T cell clones were not expanded in time to a cell count that would yield both 
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sufficient amounts of RNA to perform TCRB sequence analysis and to establish these clones as 
long term cell lines. Expansion of these clones with the aim of establishing these as cell lines was 
regarded as more crucial and thus performed instead.  
 
Control            L33             Control            L33












Figure 3.13 Of 28 proliferating Donor 8 clones, 9 were defined specific to HPA-1a by IFNγ/IL-4 ELISPOT. 6 of 
these were sorted based on TNF secretion after L33 restimulation, 1 was sorted from TNF-producing cells after 
restimulation with HPA-1a+ platelets and 1 was sorted from a population of cells co-cultured with HPA-1a+ platelets 
with down regulated CD4 expression, as summarized in table 3.9. 
 
 
Table 3.9 Summary of proliferating clones from Donor 8 after sorting and expansion 
Stimuli Detection Proliferating clones HPA-1a specific clones 
L33 peptide TNF secretion 13 (of 60 sorted) 6 (46.2 %) 
HPA-1a trc. TNF secretion 6 (of 60 sorted) 2 (33.3 %) 
HPA-1a trc. CD4 down-regulation 3 (of 60 sorted) 1 (33.3 %) 




Table 3.10 Summary of the TCRB rearrangements for 5 of the HPA-1a-specific Donor 8 T cell clones isolated after 
optimizing enrichment and detection of HPA-1a-specific CD4 T cells 
  TCRB rearrangements    CDR3 
Clone TRBV TRBD TRBJ TRBC   Length Amino acid sequence 
D8T115 11-1*01 2*01 2-1*01 2   13 ASSFRPRGVNEQF 
D8T116 6-5*01 1*01 1-3*01 1  16 ASSPSPPVPGSGNTIY 
D8T117 7-2*01 or 7-2*04 2*01 2-1*01 1 or 2   12 ASTLAGVTHEQF 
D8T118 11-2*01 1*01 2-7*01 2  15 ASSLTTGDLTSYEQYF 
D8T121 20-1*04 or 20-1*05 or 20-1*06 2*02 2-7*01 1 or 2   13 SARALAGGAYEQY 
 
These findings demonstrate that the efficiency in identifying and isolating HPA-1a-specific T cell 





The work performed in this study showed that by optimizing culturing conditions during 
enrichment, as well as finding new strategies for identifying populations of proliferating antigen-
specific T cells, the cloning efficiency of single HPA-1a specific CD4 T cells improved. HPA-1a-
specific T cells can be isolated after a single stimuli compared previous isolations requiring 
several rounds of stimulation (47;48). Several observations during the course of this study lead to 
an improved strategy for enrichment, detection and isolation of HPA-1a-specific T cells from 
PBMCs of alloimmunized women: 
 
4.1 CD4 T cells that proliferate in response to HPA-1a antigen stimuli exhibit 
down-regulation of surface CD4 expression 
HPA-1a-specific T cells down-regulate CD4 in response to antigen-specific stimulation. This may 
be used as a hallmark of activation to distinguish these cells from proliferating cells with 
irrelevant specificities in the CFSE proliferation assay, as demonstrated in this study. 
 
From the region of CD4 down-regulating T cells, three HPA-1a-specific T cell clones were 
isolated. TCRBV analysis revealed that these three single sorted cells originated from two distinct 
clones. However, these count as three identified and isolated antigen-specific T cells as they were 
detected and isolated separately. The separate isolation of several single cells from the same clonal 
lineage should be expected, as the cells are isolated from a population of T cells that have 
undergone a number of cell divisions.   
 
After 14 days in culture, more proliferating CD4 T cells were present in HPA-1aa stimulated 
culture than in culture stimulated with HPA-1bb platelets, and a distinct population of 
proliferating T cells with down-regulated expression of CD4 on the surface was detected in the 
HPA-1a stimulated culture only. It has been demonstrated that internalization of the CD4 
molecule occurs as a part of the regulation of the signalling events that mediate T cell activation. 
Modulation of surface CD4 expression in response to activation through the TCR complex has 
been reported, but the results are not consistent. Rapid down-regulation by internalization and 
subsequent lysosomal degradation of CD4 has been reported to occur within hours after activation 
by both monoclonal antibodies targeting the TCR complex, phorbol esters and specific antigen, 
followed by a recovery around 20 hours after stimulation (64-66). Another study reported a 
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marked down-regulation of surface CD4 expression 24 hours after stimulation of antigen-specific 
T cells with appropriate antigen without recovery after 48 hours (67). However, these studies have 
been performed on clonal T cell lines in vitro, and may not reflect the time course of CD4 
expression during an immune response in PBMC tissue cultures in vitro where APCs, antigen and 
other immune cells are present or during in vivo immune responses. 
 
The observation of CD4 down-regulation in a population of proliferating CD4 T cells 14 days 
after HPA-1a antigenic stimuli, and the presence of HPA-1a-specific T cells in this population 
(and not in the population of constitutive CD4 levels) suggests that the CD4 down-regulation that 
has been reported in connection with T cell activation may be a consistent physiological feature of 
HPA-1a-specific CD4 T cells. On the other hand, the cells are co-cultured with appropriate 
antigen for 14 days in the presence of antigen presenting cells, added IL-2 and other immune cells 
which secrete cytokines and other stimulatory molecules, suggesting that activated cells displaying 
down-regulated levels of surface-bound CD4 may have been re-stimulated several times during 
the enrichment. 
 
A study published in 1997 showed that after immunizing Lewis rats with various antigens known 
to induce experimental allergic encephalomyelitis (EAE) in animal models, CD4 levels were 
down-regulated on CD4 T cells on days 4 and 10 after EAE induction in vivo and restored by day 
21 (68). Although this observation may not be completely applicable to this present study, it is 
very interesting to see that CD4 modulation varies in both time-course and extent in different 
settings of T cell activation studied in different experimental models.  
  
4.2 HPA-1a-specific T cell clones are likely to be the dominating T cells 
responding to foetal platelets in connection with NAIT 
In this study, T cell clones isolated from cells proliferating in response to stimulation with HPA-
1a-positive platelets were subsequently found to be specific for HPA-1a, by using peptide-pulsed 
APCs. The ability of the synthetic HPA-1a-derived L33 peptide to elicit an immune response in 
clones that were isolated after stimulation with whole platelets (Figure 3.2), meaning that they 
never previously encountered the synthetic L33 peptide, strongly suggests that the immune 
response to HPA-1a platelets in vivo is directed towards the L33/P33 polymorphism of the HPA-1 
antigen. This observation fits well with the observation by Anani et al, who demonstrated that the 
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peptide fragments naturally processed and presented from the extracellular domain of β3-integrin 
by HLA-DRB3*0101 homozygous APCs were derived from HPA-1a (69). 
 
However, further investigations are needed to examine the role of other alloantigens on foetal 
platelets, e.g. paternally inherited MHC class I molecules, which could also elicit allo-specific T 
cell responses (by indirect mechanisms). Because the polymorphism of MHC molecules, pending 
experiments will be conducted with the child’s own platelets (or paternal platelets) to assay for 
recall responses to allogene MHC. 
 
4.3 No distinct expression patterns of surface activation markers were 
observed in HPA-1a-specific T cells 
The observation of CD4 down-regulation on activated HPA-1a specific CD4 T cells encouraged 
the investigation of other phenotypic properties that may distinguish cells proliferating in response 
to HPA-1a antigen from other cells proliferating with no obvious source of antigen-stimulation. 
The surface marker phenotyping was performed in order to see whether T cells activated 
specifically through the TCR were phenotypically distinguishable from other T cells proliferating 
in response to other stimuli. The expression pattern of various activation-, subset- and homing 
markers (Table 2.11) on HPA-1a specific T cells and the comparison of such patterns on various 
other cell populations (section 3.4) revealed no obvious phenotypical properties (expression 
pattern) that would allow the specific detection of HPA-1a specific T cells. 
 
4.4 Proliferation of CD4 T cells with irrelevant specificities was reduced by 
replacing foetal bovine serum (FBS) with human serum in the culture 
medium during enrichment of antigen-specific T cells  
One of the main challenges of the CFSE proliferation assay is that other T cells than those specific 
to the appropriate antigen will also proliferate. The potential sources of stimulation of these cells 
are not known, but they may be derived from various substances such as antigens present in the 
culture medium supplements, such as added serum. Other possible sources of stimulation may be 
contact with other cells, cytokines added to the cultures (or present in the serum supplement) or 
produced by the cultured cells or activation by antigen in vivo before or during blood sampling 
from the blood donor. 
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The CFSE proliferation assay performed on PBMCs from CMV positive donors (Table 3.4) on 
day 6 of proliferation at atmospheric O2 content show reduced background proliferation when 
using culture medium supplemented with human serum only, compared to medium supplemented 
with 10 % FBS. The parallel assays enriched at 5 % O2, thought to mimic physiological 
conditions, show no indications of improved enrichment of antigen-specific CD4 T cells 
compared to proliferation at atmospheric O2 levels. The same was observed at day 14 after 
stimulation.  
 
The improved enrichment of potential antigen-specific CD4 T cells observed when replacing FBS 
with human serum indicates that some of the background proliferation observed in previous assays 
may be derived from bovine antigens present in the FBS, or that growth factors known to be 
plentiful in FBS drives proliferation of cells that are not HPA-1a-specific. It is possible that 
background proliferation may be reduced further by using serum-free culture medium, but by 
removing serum completely, important growth factors, other nutrients and protecting protein will 
be lost, and may compromise the proliferation of the desired cells as well as the cells that 
proliferate “spontaneously”. 
 
The time course of the CD4 immune response monitored in these assays also indicate that the 
optimal time point of isolation of potential antigen-specific CD4 T cells is closer to 6 or 10 days 
than 14 days. The CFSE proliferation assay performed on day 14 with CMV peptides (Table 3.4) 
showed a massive proliferation of both potential antigen-specific cells as well as cells with 
irrelevant specificities, while at days 6 and 10 both low background proliferation as well as 
improved enrichment of potential antigen-specific cells was observed. This applies for the last 
proliferation assay performed with HPA-1a antigen on donor samples. 
 
On day 10 of stimulation with HPA-1a antigen on Donor 8 PBMCs (Figure 3.11 and Table 3.8) 
the enrichment of antigen-specific cells seems to be much higher in platelet-stimulated cultures 
relative to peptide-stimulated cultures. This is an interesting observation, as stimulation with 
whole platelets will better resemble the activation of a T cell response to HPA-1a in vivo. One of 
the possible explanations for this, may be the generation of peptide fragments of different lengths 
when the HPA-1a antigen is processed by antigen presenting cells (69) and that a heterogeneous 
pool of peptide derived from the same antigen may engage a higher number of reactive T cells 
than a homogenous pool of identical, synthetic peptide. However, studies with the isolated HPA-
1a-specific T cell clones show that they respond to both native antigen and synthetic peptide. 
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4.5 Combining the CFSE proliferation assay with surface-TNF detection 
dramatically improved the specific detection and isolation of HPA-1a-
specific CD4 T cells 
Capturing TNF produced in response to re-stimulation with L33 antigen on the cell surface 
improved the detection and isolation of HPA-1a-specific CD4 T cells. The complete elimination 
of CD4 T cells that proliferate without any obvious source of antigen stimuli in the CFSE 
proliferation assay, even with the most optimal enrichment conditions, is not likely. However, 
modifications of the culturing conditions during enrichment of CMV antigen-specific T cells from 
CMV-positive donors helped reduce the proliferation of CD4 T cells with irrelevant specificities 
when applying these modified conditions to the enrichment of HPA-1a specific CD4 T cells.  
 
By applying the surface TNF assay to the isolation of single proliferating CD4 T cells in 
combination with optimized enrichment of antigen-specific CD4 T cells, the cloning efficiency 
improved markedly. The assay allowed the direct detection and viable isolation of proliferating 
CD4 T cells producing TNF in response to recent re-stimulation with HPA-1a antigen. Isolation of 
single proliferating, TNF secreting CD4 T cells yielded 13 clones from peptide stimulated culture 
and 6 clones from HPA-1a platelet stimulated cultures. Among these, 6 and 2 clones were HPA-1a 
specific, respectively. This finding demonstrates that a combination of the CFSE proliferation 
assay and TNF-surface detection after a subsequent stimulation with antigen dramatically 
improved detection of HPA-1a-specific T cells. 
 
The surface TNF assay was not as efficient when applied to the platelet-stimulated cultures 
compared to the culture stimulated with peptide. The reason for this may be that the incubation 
time of only 4.5 hours did not allow the processing and presentation of sufficient amounts of 
antigen to stimulate the T cells at the same extent as peptide fragments pulsed directly to the 
HLA-DR52a molecules on the APC surface. In addition, peptide can bind directly to HLA-DR 
molecules expressed by the T cells (Table 3.5-3.7) allowing them to stimulate each other (Figure 
3.9), in addition to the antigen presenting cells. Optimization of the assay applied to platelet 
stimuli was not performed, partially because such optimization was beyond the scope of this 
present study, and partially due to limited access to patient sample.  
 
Single proliferating cells from a region of CD4 down-regulation and a region of constitutive CD4 
levels were isolated from platelet-stimulated culture and gave rise to 3 and 6 proliferating clones, 
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respectively. One of these, originating from the region of CD4 down-regulation, was HPA-1a-
specific. 
 
The secretion of TNF in response to T cell activation is by no means restricted to apply to HPA-
1a-specific T cells. There is reason to believe that this method for detecting and isolating antigen-
specific T cells will be applicable to others who are working with T cell responses and wish to use 
clonal T cell lines for such studies. 
 
The cloning efficiency with the assay proposed here is still not completely optimal. The HPA-1a 
specific T cells that are sorted and expanded, have divided several times in culture, and with a 
hypothetical cloning efficiency of 100 %, one would expect the same clone to be present in several 
wells after sorting and expansion. Since this is not the case with the sorting assays performed in 
this study, there is reason to believe that further optimisation measures can be made to increase the 
cloning efficiency additionally.  
 
One must be aware that the different clones that are isolated here may, although all HPA-1a-
specific, behave differently and display different features that might reflect diversity in T cell 
response associated with NAIT. The different clones use different TCRB genes, giving different 
CDR domains. Although specific to the same antigen, the different TCRs will recognize the same 
antigen in different ways, and these clones are valuable tools for mapping the common epitope 
recognized by different T cell receptors.  
 
In addition, the clones display slightly different cytokine profiles in response to activation. As 
demonstrated by the ELISPOT assays performed in this study (Figures 3.2 and 3.13), some clones 
secrete only IFNγ, some secrete both IFNγ and IL-4 and one clone, D8T20, secrets IL-4 and no 
IFNγ in response to HPA-1a stimuli. If different clones have different patterns of cytokine 
production, and if these patterns change during the time course of an immune response, specific T 
cells may be overlooked when using detection strategies based on TNF production. This 
observation stresses the importance of optimizing different enrichment and detection strategies if 
one wants to isolate and study different T cell clones. In this study, two such strategies are 
optimized based on CD4 expression and TNF production. In addition, T cell clones can potentially 
be detected on the basis of other cytokines secreted in response to stimuli, i.e. by applying the 
Cytokine Secretion Assay detecting IFNγ- or IL-4 secretion to these protocols (70;71). 
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5. Future perspectives 
The strong association between a specific MHC allele and immunization to HPA-1a, along with 
the identification of HPA-1a-specific T cells in the circulation of previously immunized women 
suggests that the activation of T cells may be the most critical event of the immune response that 
leads to the production of maternal HPA-1a-reactive antibodies. If this is the case, therapeutic 
strategies aimed to prevent activation of these T cells in HPA-1bb women will be the most rational 
therapy of choice.  
 
For decades, immunotherapeutic strategies to enhance or suppress immune responses have been 
subject to intensive investigation. For a number of diseases including various cancers, rheumatoid 
disorders and autoimmune diseases, immunomodulatory strategies aiming to suppress T cell 
activation have revealed promising results.  
 
HPA-1a-specific T cell clones may serve as useful tools to develop similar strategies for 
prevention of NAIT by preventing the activation of HPA-1a-specific T cells that may be present in 
HPA-1a-negative individuals. By identifying the common TCR epitope within the HLA-
DR52a:HPA-1a peptide-complex, amino acid substitutions may be performed to develop synthetic 
peptide that may block activation of HPA-1a-specific T cells by binding to HLA-DR52a with 
higher affinity than HPA-1a peptide without activating these T cells. Another strategy may be to 
prevent HPA-1a mediated activation of specific T cell activation by inducing tolerance to HPA-1a 
in these T cells, i.e. through anergy, a strategy proven successful in other disease models, such as 
allergies, as reviewed by Akdis and Akdis (72). 
 
The most potentially specific way of detecting HPA-1a-specific T cells in PBMC cultures in 
controlled in vitro experiments, is by using multimeric recombinant MHC:peptide (pMHC) 
complexes. Recombinant HLA-DR52a molecules with HPA-1a-derived L33 peptide in the peptide 
binding groove can be multimerized by biotinylating the tails of the MHC class II molecules and 
joining these together to a tetrameric complex via a streptavidin core with four binding sites for 
biotin. By using a streptavidin core conjucated to a fluorochrome, T cells that have bound the 
pMHC-complex can be visualized directly by flow cytometry and isolated by FACS sorting. 
These tetramers can have many other applications in investigating the immune response, i.e. by 
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Appendix I. CFSE proliferation assays of PBMCs from CMV positive blood donors 
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Figure A.1 – CFSE proliferation assay performed in atmospheric O2 content of PBMCs from two CMV-positive 










10 % FBS, 4 % Human Serum                    10 % Human serum
No stimuli                           pp65                   No stimuli                         pp65
 
Figure A.2 – CFSE proliferation assay performed in 5 % O2 content of PBMCs from two CMV-positive donors on 












10 % FBS, 4 % Human Serum                      10 % Human serum
No stimuli                           pp65                   No stimuli                               pp65
 
Figure A.3 – CFSE proliferation assay performed in atmospheric O2 content of PBMCs from two CMV-positive 











10 % FBS, 4 % Human Serum                      10 % Human serum
No stimuli                               pp65            No stimuli                               pp65
 
Figure A.4 – CFSE proliferation assay performed in 5 % O2 content of PBMCs from two CMV-positive donors on 











10 % FBS, 4 % Human Serum                       10 % Human serum
No stimuli                          pp65                  No stimuli                           pp65
 
Figure A.5 – CFSE proliferation assay performed in atmospheric O2 content of PBMCs from two CMV-positive 











10 % FBS, 4 % Human Serum                   10 % Human serum
No stimuli                          pp65                No stimuli                          pp65
 
 
Figure A.6 – CFSE proliferation assay performed in 5 % O2 content of PBMCs from two CMV-positive donors on 
day 14 of stimulation.  
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Appendix II. CFSE proliferation assays of PBMCs from an HPA-1a immunized HPA-1bb 
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LolP1                                        L33
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Figure A.7. CFSE proliferation assay of Donor 8 PBMCs on day 6 of stimulation 
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Appendix III. TCRB sequence analysis of HPA-1a-specific T cell clones isolated with 
optimized enrichment- and detection strategies 
 
 
Figure A.8. Sequence alignment for HPA-1a-specific T cell clone D8T115 
 
 
Figure A.9. Sequence alignment for HPA-1a-specific T cell clone D8T116 
 
 
Figure A.10. Sequence alignment for HPA-1a-specific T cell clone D8T117 
 
 








 the proposed amino acid sequences of the T cell receptor CDR3 domains 
, D8T116, D8T117, D8T118 and D8T121. This analysis was performed using 
 available at http://www.imgt.org.  IMGT unique numbering for V-domains 
GT (62). 
 
Figure A.13. Schematic visualization of
(purple) of T cell clones D8T115
the IMGT/Collier-de-Perles tool
determines the lengths of CDR-IM
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